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Currently, a large amount of personal genomic data can be generated at an affordable price in a 
short period of time due to the improvement in the DNA sequencing technologies. Abundant 
research results on genetic diseases have been published in recent years. Therefore, it is 
eventually possible to integrate multiple types of information together and apply them into 
genomic-based personalized healthcare. However, this is still a very challenging task for 
healthcare professionals because the desired information is hidden in highly complex and 
heterogeneous genomic data sets and spread in various databases, which were typically created 
for researchers. In this research project, a personal genomic information management and 
analysis system is created for healthcare professionals, especially physicians.  
To properly design such a system, an exploratory survey was conducted to identify the 
current status of physicians in using genomics in their clinical practice and to collect their 
expectations about the features of a patient genomic information system. The results of this study 
indicated that physicians have sufficient knowledge in genomics and they are interested in 
incorporating genomics into their clinical practice. The results also indicated that a well-designed 
patient genomic information system with desired features can help physicians to incorporate 
genomics into their clinical practice.   
Based on the survey findings, a personal genomic information system was created for the 
purpose of managing and analyzing patient genomic data. In this system, we first created an 
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integrated database, and then developed data analysis algorithms to extract clinical information 
from patient genetic variation data, including disease-associated genetic variations and 
pharmacogenomic associations. Physicians can conveniently identify the genetic reasons for 
diseases and determine personalized treatment options based on the information provided by the 
system. 
A usability study was conducted to obtain physicians’ feedback about the system after 
they use it to finish some tasks such as searching the genetic variations of one patient, 
determining the patient’s risk of certain diseases, and identifying the corresponding 
pharmacogenomic results. The results of this study indicated that physicians could easily find the 
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1.0  INTRODUCTION 
This chapter introduces the background, significance, and the challenges of this research project. 
1.1 BACKGROUND 
In recent years, by using the high-throughput sequencing technologies, large amounts of personal 
genomic data have been generated [1]. Genomics research in the past one and a half decades has 
provided a better understanding of the human genome and genetic foundation of diseases. The 
availability of both genomic data and extensive knowledge in genomics makes it possible to 
determine the risk of developing certain diseases or individual response to drugs by comparing 
personal genomic data with published research results [2], which is the foundation of 
personalized medicine.  
At this moment, genomic data, genomics research results, and other useful resources for 
healthcare are spread in many places such as in disparate databases, web services, software 
programs, and journal articles. For a well-trained researcher in genomics, it is not difficult to 
obtain gene details from Genbank [3], to perform a query in dbSNP [4], to retrieve a record from 
Online Mendelian Inheritance in Man (OMIM) [5], to perform a sequence alignment using 
BLAST [6], and to combine the collected information together to evaluate the results published 
in a Genome-Wide Association Study (GWAS) research project. However, these tasks are 
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challenging for current healthcare professionals (physicians, nurses, health IT professionals) 
since most of them did not receive extensive training in genomics [7]. Therefore, to make the 
personal genomic information easily accessible and meaningful for healthcare purposes, 
sophisticated information integration, data management, and data analysis systems are needed. 
1.2 SIGNIFICANCE 
The goal of this project is to create a sophisticated, internally consistent, and scalable system that 
can collect, analyze, and integrate different types of genomic data, and organize them into a 
structured format so that it is convenient for physicians and other healthcare professionals to use 
[1, 8]. Data are stored in a central database that can be used by programs in the system to 
perform various tasks such as variation analysis, report generation, and other tasks specific to 
research [9] or clinical practice [10]. This system enables physicians to utilize the available 
patients’ personal genomic data and up-to-date reliable research results so that they can have 
accurate diagnosis results and create personalized treatment plans, which are the early steps of 
personalized medicine [11-13]. In order to keep the system up-to-date, the data extraction scripts 
and data process algorithms need to be updated periodically. 
1.3 CHALLENGES 
To create such a system, there are several challenges. The first challenge is the complexity and 
large size of genomic data sets. For instance, a personal genome sequence alone has three billion 
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base pairs and the information in this sequence is complex. Furthermore, personal genomic data 
are complex in nature [14] and contain heterogeneous data types such as DNA sequences, RNA 
sequences and structures, protein sequences and structures, gene expression profiles, and DNA 
methylation profiles. They are all relevant to genetic diseases or metabolic responses to drugs in 
a certain way.  
The second challenge relates to the need for integration of different types of genomic data 
from various sources while each data source has its own unique format. Each type of genomic 
data has its own unique structure and is stored in databases in different formats [15] such as plain 
text sequences, matrices, information description files, tables, and diagrams. Because of some 
historical reasons, different databases may use different names to refer to the same gene, or report 
the positions of genetic variations without explicitly indicating the reference genome used. Thus, 
the integration of heterogeneous genomic data types from different data sources is challenging 
[16]. 
In the field of genomics, there are often revisions and changes in databases caused by new 
discoveries [17]. Examples of these changes include updates on the reference genome, updates on 
annotation of certain genes, and newly identified Single Nucleotide Polymorphisms (SNPs). This 
leads to the third challenge in genomic data integration, rapidly updating data sources, which 
often means the data extraction scripts and data process algorithms need to be updated 
accordingly.  
Because of these challenges, it is typically difficult for healthcare professionals such as 
physicians to collect desired information from multiple sources and confidently apply the 
information into their clinical practices, especially if they have not received sufficient training in 
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genomics. Our system simplifies the whole process and makes the desired information easily 
understandable and accessible for physicians. 
The system we have developed performs genomic data management and genomic data 
analysis; integrates data from multiple sources and organizes them into a structured format in 
databases; and generates easy-to-understand reports for physicians. It provides one single place 
for various types of information needed by physicians in personalized medicine practice. For 
example, the physicians can just enter a patient ID and a disease name in the search area of the 
system and the system automatically performs database queries, genomic data analysis, and a 
report that includes information about the genetic variations of the patient related to the given 
disease. One important advantage of the system is that it allows physicians to get their desired 





2.0  LITERATURE REVIEW 
This chapter provides a review of the available literature about personalized medicine, genetic 
variation data types, genetic variation databases, genetic variation data management, and genetic 
variation data analysis systems.  
2.1 PERSONALIZED MEDICINE  
Personalized medicine utilizes personal medical information to tailor strategies and medications 
for diagnosing and treating diseases in order to maintain people’s health [18]. In this medical 
practice, physicians combine results from all available patient data (such as symptoms, 
traditional lab results, medical history and family history, and certain personal genomic 
information) so that they can make accurate diagnoses and determine personalized treatment 
strategies accordingly [11]. Health information management (HIM) professionals will play a 
critical role in this personalized healthcare practice because they are responsible for managing 
patient data. 
With the improvement of high-throughput biotechnologies and the rapid decrease in 
DNA sequencing cost and time, genomic-based personalized medicine has already been 
practiced in a number of places, including Geisinger Genomic Medicine Institute, Scripps 
Health, Cleveland Clinic, Vanderbilt University Medical Center, and the Medical College of 
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Wisconsin [1]. Doctors have ordered whole-genome sequencing for their patients, and other 
healthcare professionals have performed genomic data analysis to identify genetic reasons for 
certain diseases that cannot be determined by conventional approaches [19]. Some hospitals, 
such as Children’s Mercy Hospital in Kansas City [20] and the University of Pittsburgh Medical 
Center [21] have started to consider or have already taken the first few steps toward genomic-
based personalized medicine. 
2.1.1 Challenges in genomic-based personalized medicine 
Challenges of practicing genomic-based personalized medicine can be divided into four 
categories [1, 22-24]; 1) the massive volume and complexity of genomic data from high-
throughput technologies; 2) difficulties in genomic data analysis, such as information extraction, 
reporting, and database building; 3) difficulties in applying personal genomic information into 
clinics; and 4) challenges in personal genomic data security and privacy. 
2.1.1.1  Challenges related to genomic data management 
Today, there is a rapid increase in the use of the high-throughput biotechnologies, such as next-
generation DNA sequencing technologies [25] for whole genome sequencing, microarray for 
gene expression patterns, RNA-seq [26] for identifying all transcripts of genes and their 
expression patterns; ChIP-seq [27, 28] for determining all regulatory elements in a genome; and 
MDB-seq [29] for collecting DNA-methylation profile genome-wide. These technologies can 
generate huge amounts of data in a short period of time.  
The Human Genome Project (HGP) [30-32] was conducted from 1990 to 2003 for the 
purpose of sequencing and understanding the human genome. The total cost of the HGP was 
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about $3 billion, and one human genome was sequenced. In recent years, next-generation 
sequencing (NGS) technologies have dramatically reduced the DNA sequencing cost. The price 
dropped sharply from $3 billion to $100 million in 2007, then to roughly $1.5 million in 2008, 
[33] and to roughly $6,000 in 2012 [34, 35]. By the end of 2015, one could sequence a human 
genome in 24 hours at a cost of roughly $1,500 [35]. The commercialization and wide 
application of more advanced DNA sequencing technologies currently in development will 
further reduce the sequencing cost and increase the speed. 
Organizing and managing these raw genomic data sets can be a big challenge. One other 
issue is the management of complex genomic data sets. Multiple types of genomic data are 
generated from different technologies and platforms [17].  
2.1.1.2 Challenges in personal genomic data analysis 
The next category of challenges is genomic data analysis. Extracting valuable information from 
large data sets is a difficult task. The situation is even worse when the data sets themselves are 
complex [14]. Genomic data sets include different types of data [15], such as DNA sequences, 
RNA sequences and structures, protein sequences and structures, and gene expression profiles. 
Each data type has its own characteristics and none of the data sets are simple to analyze, 
especially when its volume is large. For instance, analyzing a DNA sequence with 300 
nucleotide bases is not difficult, but identifying a short, informative DNA segment from 3 billion 
nucleotide bases (which is the length of a human genome) is a nontrivial task. 
In parallel to the astonishing advancement of high-throughput technologies is the 
significant progress researchers have made in understanding the disease at the molecular level in 
the past decade [36]. Before the HGP, it was quite difficult and time-consuming to sequence 
even a small genome [37], and therefore scientists could only focus on analyzing one gene or a 
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few genes in their research projects. Consequently, researchers believed that most genetic 
diseases are caused by mutations in one gene or a few genes. However, post-HGP research has 
indicated that this understanding was not correct. Further investigations performed on the human 
genome and other species’ genomes have demonstrated the complexity of these genomes [38]. 
The associations between disease and genomic information have been extended from one single 
gene to multiple genes in one or multiple chromosomes [39]. 
With the great advancement in research, scientists have a better idea of the association 
between genetic variations in genomes and the patients’ risk of developing certain diseases, and 
patients’ possible responses to some drug therapies. On the other hand, these extensive research 
results also make it challenging to analyze personal genomic data for healthcare purposes. For 
example, in the past, when doctors wanted to determine the genetic reason for sickle cell anemia 
in a patient, they would only check one point mutation in the hemoglobin beta gene (HBB), a 
mutation that leads to a change in the shape of the red blood cell [40-42]. Therefore, the data 
analysis procedure could be quite simple. Today, with the availability of extensive genomic data 
sets, researchers know that genetic variations in multiple genes might be associated with sickle 
cell anemia. The task of determining the precise genetic reason for one patient’s condition can be 
much more difficult. To make the situation worse, some research results from different research 
groups are not consistent [43] and directly conflict with each other. 
Highly skilled genomic data analysts, well-designed databases and accurate research 
results, sophisticated algorithms and software programs, and sufficient computational power are 
needed for genomic data analysis [44]. At this moment, these resources are typically not 
available to most physicians. Even if one can easily access excellent genomic data analysis 
programs (which are available for certain types of data sets) and powerful workstations, it is still 
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challenging for most healthcare professionals to select the best program and the correct 
parameters for that particular data set because they typically do not have the required training in 
this field. 
2.1.1.3 Challenges in applying personalized medicine into clinics 
For healthcare purposes, one critical piece of information is which genes and mutations are 
involved in the development of a disease [45]. Decades ago, scientists already could determine 
associations between mutations in some genes and certain diseases. Recent technological 
advances have made it possible to determine the role of specific genetic variations in genetic 
diseases in large-scale genome-wide analyses [46]. However, the newly generated research 
results are overwhelming (hundreds of papers have reported genetic variations associated with 
one disease, and many of them have reported completely different variations) and sometimes 
even conflict with each other. Therefore, applying them in clinical practice is another challenge 
in genomic-based personalized medicine. 
Since the cost of sequencing a human genome has sharply dropped to an affordable level 
and DNA sequencing may become a routine task in hospitals in the near future, physicians 
already realized the potential of genomics to improve clinical practice [10]. One expensive and 
challenging task for obtaining clinically useful information is analyzing these large-scale 
sequences and other genomic data files, connecting the analysis results with research results in 
the literature [47], and linking the results to the EHR in a meaningful way. 
2.1.1.4 Challenges in personal genomic data security and privacy  
Personal genomic data are highly sensitive [48] and need to be protected properly because each 
record contains not just the health information about one particular patient, but potentially, 
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information about a large group of people who have a blood relation with the person who takes 
the genetic test. This impact can last for generations because the genomic information will be 
passed to these people’s descendants. In addition, by using some algorithms and data collected 
from public databases and social media, it is already possible to uniquely identify the owner of a 
de-identified genome sequence stored in public databases [49, 50].  The privacy of the individual 
and his or her relatives may be threatened, and the confidentiality of the personal genomic data is 
lost. The threat to the individual’s offspring could be even more serious because research in 
genomics will likely enable the discovery of more information from a human genome in the 
future. Therefore, a stronger and more sophisticated security measure may be needed for 
personal genomic data protection, and this security measure should be set up before the wide 
application of genomic information in clinical practice. 
2.1.2 Current solutions to the challenges 
2.1.2.1 Genomic data management 
NGS technologies can produce an enormous amount of sequencing data in a short time, and 
therefore storing and managing these huge data sets can be challenging. One straightforward 
suggestion is to apply a compression algorithm to reduce the sizes of these sequences [51]. A 
basic fact about the human genome is that genome sequences of two unrelated individuals are 
highly similar (roughly 99 percent identical) [52]. Therefore, directly storing hundreds and 
thousands of human genome sequences in a database would be highly redundant. One alternative 
approach is to keep only one reference genome (3 billion bases) and record all the differences 
between other human genomes and this reference genome. This approach can significantly 
reduce the size of stored data. Christley and colleagues combined these two approaches 
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(compression and storage of differences only) and reduced the information about one human 
genome from 3 gigabytes to about 4 megabytes [53]. In other words, the obtained data set is 750 
times smaller than its original size. This approach also has problems. For instance, the 
information in the data set depends on the reference genome. Once the reference genome is 
updated, all the information in the stored data set needs to be updated as well. When the database 
contains a huge number of patient genomic records, this information update process may take 
significant time. Table 1 summarizes the advantages and disadvantages of these approaches. 
Table 1. Advantages and disadvantages of DNA sequence storage strategies 
Data Storage Strategy  Advantages  Disadvantages  
Saving as a plain text file  Easy to retrieve and analyze the 
sequence  
Large file size (3 GB/genome)  
Saving as a compressed file  Smaller file size (roughly 1.5 to 2 
GB/genome)  
Time required (can be hours) to 
perform compression and 
decompression before data 
analysis  
Saving only differences between 
the genome and the reference 
genome and compressing the file  
Very small file size (4 
MB/genome)  
Time required to rebuild the 
needed DNA sequence; need to 
update all the files when the 
reference sequence is changed 
 
Some information systems are specifically dedicated to the management of large-scale 
biological information. For instance, openBIS is a distributed information system that can be 
used for managing DNA sequences generated by NGS technologies [54]. 
For the challenging task of integrating different types of genomic data and organizing 
them in a way that is convenient for clinicians to use in their practices, the current solution is just 
to store different genomic data sets in different databases and provide links between certain items 
within those databases. The genomic databases created by the National Center for Biotechnology 
Information (NCBI) [55] are an example of this solution [56]. These databases can be very 
useful. However, physicians and other healthcare providers face a serious challenge to fully 
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utilize or correctly combine useful data items from multiple databases because this information 
integration task requires extensive knowledge of genetics and genomics to accomplish. 
2.1.2.2 Personal genomic data analysis 
Because of the complexity of genomic data, many people have realized that it is necessary to 
enhance education in genetics and genomics [57] for future healthcare providers. Such education 
is apparently beneficial. On the other hand, expecting every physician to become an expert in 
human genetics and genomics and keep track of the research progress in these fields would not 
be reasonable. It is also not reasonable to expect a physician to search the scientific literature to 
find out all the factors related to one common genetic disease so that he or she can order the 
correct genetic test or genomic analysis for the patient. After all, the research literature may 
contain many papers about one common disease and results in those papers do not necessarily 
agree with one another. Physicians would face significant difficulty in determining which results 
are applicable to their specific patients. For similar reasons, it would be equally challenging for 
physicians to use the literature to determine the correct drug and dosage for their patients. This 
scenario is quite different from the literature searches that physicians need to do occasionally on 
rare diseases. In that case, the difficulty is to identify the small number of papers about the rare 
disease among a huge number of irrelevant articles. In genomic-based personalized care, 
physicians deal with common diseases (such as cancer, obesity, cardiovascular disease, and 
diabetes) in a different way, and the difficulty is to identify the most suitable information for 
each patient from a large number of highly relevant articles. Therefore, the available genomics 
research results should be preprocessed and organized in a certain way before they are presented 
to physicians for diagnosis and treatment purposes. 
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Although most clinical sites, especially small healthcare facilities, do not have highly 
sophisticated genomic data analysts, skilled programmers, or high-performance computers for 
large-scale data analysis, they may use resources from large sequencing centers and cloud-based 
computing platforms to have those tasks done with low costs [58, 59]. Large genome-sequencing 
centers have well-trained genomic data analysts and extensive experience in processing large-
scale genomic data. Cloud-based computing facilities (e.g., Amazon Web Services) can 
configure their high-performance computers according to the requests from their customers and 
conduct intensive computation tasks. The customers do not need to hire dedicated software 
engineers or purchase and maintain expensive high-performance computers. Some genomic data 
analysis pipelines are already available for this approach. One example is the Atlas2-Cloud 
pipeline [60, 61]. This pipeline has been successfully implemented into Amazon Web Services.  
2.1.2.3 Applying personalized medicine into clinical practice 
Integrating genetic analysis into clinical practice requires a radical change in the process of data 
collection, management, and analysis. It’s becoming increasingly important to determine the 
level of evidences required to assess and evaluate the genetic variations based on their effect on 
patient’s care. For example, a variant that requires a change in diet might need less evidence than 
one that requires a surgical procedure [62]. The success in integrating genomic data within 
clinical practices and the implementation of personalized medicine depends on the ability to 
analyze the scalable amount of genetic variations data. Some tools and software have been 
developed to analyze genetic variations data such as VAAST, GenePattern, and Gemini. These 
tools are usually used by researchers and require a good background in genetics and genomics.  
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2.1.2.4 Personal genomic information security and privacy 
Policies and laws play a key role in protecting individuals’ genetic information. The Health 
Insurance Portability and Accountability Act (HIPAA) provides the basic protection of the 
privacy of information stored in patients’ records [63]. On January 25, 2013, the Office for Civil 
Rights of the US Department of Health and Human Services published modifications to the 
privacy, security, breach notification, and enforcement rules in HIPAA under the Health 
Information Technology for Economic and Clinical Health (HITECH) Act. One of these 
modifications emphasizes that personal genetic information is protected health information and 
prohibits the use and disclosure of genetic information by any health plans for underwriting 
purposes [64]. The Genetic Information Nondiscrimination Act (GINA) is the law specifically 
created to protect individuals from discrimination based on their genetic test results [65]. GINA 
protects individuals from genetic discrimination in both health insurance and employment. 
Besides these policies and laws, many technical applications aim to protect personal 
genomic information. For instance, Interpretome [66] is a client-side genome interpretation 
system developed to analyze personal genomic data on the customer’s local machine. The 
personal genomic data and the analysis results would not leave the customer’s machine in order 
to protect this sensitive information. Another example is the GenePING system [67]. This system 
provides secure storage for genome data sets and enables the sharing of personal genetic 
variations and gene expressions by applying the Advanced Encryption Standard (AES) 
encryption algorithm.  
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2.2 GENETIC VARIATIONS 
2.2.1 Multiple types of genetic variations 
Although people look quite different, all human genomes are actually highly similar. More than 
99 percent of human genomes from two unrelated individuals are identical [68-70]. The 
differences among these genomes are genetic variations. Most of these genetic variations simply 
make us appear different: skin color, eye color, hair color, height, etc. Some of these genetic 
variations can cause diseases.  
Genetic variations refer to the differences in the DNA sequences between individuals or 
populations [71-73]. There are several types of genetic variations such as Single Nucleotide 
Polymorphisms (SNPs), copy number variations (CNVs), and short insertions and deletions 
(INDELs). 
2.2.1.1 Single Nucleotide Polymorphisms (SNPs) 
SNPs are the most common type of genetic variations that represent a difference in a single 
nucleotide [74]. SNPs represent 90 percent of the human DNA polymorphisms [75]. Figure 1 
illustrates the concept of SNPs.  
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Figure 1. SNP Representation [76] 
 
SNPs can occur anywhere in a genome. When SNPs occur within a gene or within the 
regulatory region near/inside a gene, they can affect the gene function/expressions and may 
increase the risk of developing certain diseases [77, 78].  
Researchers in pharmacogenomics have found that SNPs may be helpful for predicting an 
individual’s response to certain drugs, which is critically important for personalized medicine 
[79]. SNPs may be useful for predicting the individual response to environmental factors [80]. 
SNPs can also be used to track the inheritance of disease-leading genes within families [81].  
2.2.1.2 Copy Number Variations (CNVs) 
 The term "copy number variation" refers to an intermediate-scale genetic change. CNVs include 
both additional copies of sequence (duplications) and losses of genetic material (deletions) [82]. 
For example, A-B-C-D is a DNA sequence in a chromosome. A, B, C, and D are DNA segments. 
This chromosome can instead have the following sequences: A-B-C-C-D (duplication) or A-B-D 
(deletion). Figure 2 illustrates the concept of CNV. 
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Figure 2. CNV Representation (Reproduced from [83]) 
 
Unlike a SNP that affects only one nucleotide base, the CNV ranges from about one 
kilobase (1,000 nucleotide bases) to several megabases in size [84, 85]. The scale of this type of 
genetic change may affect multiple genes [86].  
There is an increasing concern about the effect of CNVs in developing complex diseases 
[87] since a number of CNVs overlaps with protein-coding regions [88]. CNVs were detected in 
genetic regions associated with complex neurological diseases [89] such as autism [90-92], 
Alzheimer's disease [93, 94], and schizophrenia [95-97]. 
2.2.1.3 Short Insertions and Deletions (INDELs) 
An insertion changes the number of DNA bases in a gene by adding a piece of DNA. As a result, 
the protein made by the gene may not function properly. The effect of short insertions depends 
on the number of base pairs inserted in the DNA strand. The insertion of one nucleotide may be 
more clinically significant than the insertion of 30 base pairs because the single nucleotide can 
result in a frame shift that can alter all the subsequent codons (a codon is a sequence of three 
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DNA or RNA nucleotides that corresponds with a specific amino acid or a stop signal during 
protein synthesis). If multiples of three base pairs are inserted, the translated protein has one or 
more extra amino acids [98]. Thus, its function may still be similar to the original protein.  
Short deletions occur when a part of a DNA sequence is missing [99]. The number of 
deleted nucleotides ranges from a single base to a long segment of chromosome [100]. Similar to 
short insertions, the deletion of one single base may have a more serious impact on the 
function/expression of a gene than the deletion of multiple three base pairs in a gene region. 
Figure 3 illustrates the concept of INDELs. 
 
Insertion of G 
 
Deletion of T 
Figure 3. INDELs Representation 
 
Approximately 36% of the short insertions and deletions are located within the 
promoters, introns, and exons of known genes [101] in the human genome. This means that some 
of these insertions and deletions can have an impact on human genes functions/expressions. 
Examples of diseases caused by short insertions include Huntington’s disease and Myotonic 
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Dystrophy [98]. One example of a disease that is caused by a short deletion is cystic fibrosis 
[102].  
2.2.2 Genetic variation databases 
Computer databases become increasingly important to store and organize the growing amounts 
of genomic data sets. These databases help researchers and physicians to get their needed 
information conveniently [17]. There are several databases for genetic variations data. These 
databases can be divided into two categories: 1) Genetic variation databases that provide 
information about genetic variations only, and 2) Genetic variations and disease/phenotype 
databases that provide information about the associations between phenotypes and genetic 
variations. 
2.2.2.1 Genetic variation databases 
dbSNP [103] is a bioinformatics database for SNPs created by the National Center for 
Biotechnology Information (NCBI) at the U.S. National Library of Medicine (NLM). This 
database stores all types of genetic variations < 50 bp [104]. This means that it includes different 
types of short genetic variations such as SNPs, INDELs, and microsatellite markers. dbSNP 
provides information about population-specific allele frequencies and genotypes and provides the 
validation state for each genetic variation [105].  
dbVar [106] is a database that archives large-scale genetic variations for multiple species 
and is based on various genomic studies. Users can use dbVar to search, display, and download 
genomic data from submitted studies on a number of species. Genetic variation types of dbVar 
include INDELs and CNVs [107]. dbVar is also created and maintained by the NCBI.  
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The Database of Genomic Variations (DGV) [108] is an online database that provides a 
catalog of human structural variations, including INDELs and CNVs. The database is 
periodically updated according to the results reported in peer-reviewed research articles. DGV 
aims to catalog highest quality structural variations based on the literature in a format that is 
convenient to physicians, geneticists, and biologists [109]. DGV contains only data for healthy 
control of human samples, while dbVar accepts data from all species [110]. 
2.2.2.2 Genetic variations and disease/phenotype databases 
Online Mendelian Inheritance in Man [111] is a comprehensive database that catalogues known 
diseases and their associated genetic variations. Each OMIM record has a summary of one 
disease and its relevant genes and variations in the human genome as reported in the literature 
[5]. Many links to other genetic databases such as GenBank, RefSeq, PubMed, and general and 
locus-specific mutation databases are also provided. 
The Database of Genotypes and Phenotypes [112] is a database that archives the results 
of studies in the interaction between genotype and phenotype [113]. dbGaP provides an access to 
the large-scale genetic data sets that are needed for Genome-wide Association Studies (GWAS) 
designs. These data sets include public access to study documents linked to summary data on 
specific phenotype variables, statistical overviews of the genetic information, position of 
published associations in the genome, and authorized access to individual-level data [113]. 
The Human Gene Mutation Database (HGMD) [114] is a comprehensive collection of 
gene mutations that underlie or are associated with human genetic diseases. The information in 
HGMD is manually curated from the literature [115]. Each HGMD record includes a reference to 
the first literature report of a mutation, the associated disease specified in that report, the gene 
name, symbol, and chromosomal location.  
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ClinVar [116] database provides information about the medical relevance of the genetic 
variation. It archives the relationship between the medically significant variations and the 
phenotypes [117]. Clinvar is strongly related to dbSNP and dbVar since it maintains information 
about the location of variation on human assemblies. Unlike dbSNP and dbVar, Clinvar accepts 
direct submissions of structured details of phenotype, and interpretation of functional and clinical 
significance of the genetic variations. 
SNPedia [118] is a wiki-based database. Researchers convert information presented in 
large-scale peer-reviewed genomic studies into machine-readable format, and then store the 
information in SNPedia so that the information is easily accessible to researchers.  SNPedia 
supports personal genome annotation, interpretation, and analysis. SNPedia links the genetic 
variations to information about diseases or phenotypic traits published in genomic studies [119].  
As a summary, short variations from multiple species can be found in dbSNP [120]. 
Structural genetic variations from multiple species can be found in dbvar [121]. Structural 
variations from healthy human beings can be searched in DGV [122]. The associations between 
human SNPs and disease/phenotype can be obtained from SNPedia [110]. OMIM  can be used to 
find the association between human genetic variations and diseases, including an extensive 
description of relevant genes and phenotypes [123]. dbGAP is mainly used for controlled access 
to individual genotype/phenotype data obtained from association studies [113]. HGMD can be 
used to study the association between human genetic variations and genetic diseases [124]. 
ClinVar can be used to find the relationship between the medically significant variations and 
phenotypes. Table 2 presents a quick comparison between these databases. 
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Table 2. Comparisons between different genetic variations databases 
DB Name  DB Purpose Species 
dbSNP Stores all types of genetic variations < 50 bp. All species 
dbVar Archives large-scale genetic variations. All species 
DGV Provides a catalog of structural variations, including insertion, deletion, 
and copy number variations. 
Human 
OMIM Catalogues known diseases with their genetic component. Human 
dbGAP Archives the results of studies on the interaction between genotype and 
phenotype. 
Human 
HGMD Includes a reference to the first literature report of a mutation, the 
associated disease state as specified in that report, the gene name, symbol, 
and chromosomal location. 
Human 
ClinVar Archives the relationship between the medically significant variations and 
phenotypes. 
Human 
SNPedia Converts the information in large-scale peer-reviewed genomic studies 
into machine- readable format that can be easily accessible by researchers. 
Human 
 
2.2.3 Genetic variations and disease association 
There is a long history of the study on genetic diseases [125]. However,  only after recent 
improvements in the fields of DNA sequencing [126] and SNP identification [127], researchers 
can now study the genetic variations in the whole genome and their association with diseases 
[127].  
Human diseases can be classified into two categories: simple and complex. Simple (or 
Mendelian) diseases (such as cystic fibrosis) are caused by mutations in a single gene [128, 129]. 
These mutations are considered as causal mutations. Complex (or common) human diseases 
(such as schizophrenia) result from the combined effect of multiple genetic variations and 
environmental effect [130, 131]. Genetic variations associated with complex diseases do not 
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cause diseases but indeed influence the risk of developing these diseases [132]. The interaction 
between genetic variations and environmental factors can increase the risk of developing these 
complex genetic diseases. This means that having a genetic variation is not an absolute predictor 
of developing diseases. In some cases, genetic variations can reduce the risk of developing some 
diseases. For example, a higher copy number of CCL3L1 gene is associated with a reduced risk 
of HIV (Human Immunodeficiency Virus) infection [133].  
Genetic variations that occur in the coding regions of the gene can affect the protein 
sequence, translational rate, and alternative splicing, all of which can influence the protein 
function and cause diseases. On the other hand, genetic variations that occur in the non-coding 
regions of the gene can alter the gene expression by modulating the activity of cis-regulatory 
elements [134]. 
Genome-wide association studies (GWAS) have been widely used for the discovery of 
genetic risk factors associated with human diseases. In GWAS, hundreds of thousands of SNPs 
are examined for association with a disease in hundreds or thousands of persons [46]. GWAS is 
typically based on a case–control design in which genetic variations from people with one 
disease or phenotype (cases) are compared against the ones from people without the disease of 
interest (controls) [135]. These studies catalogue and associate each clinical condition and 
phenotypic trait with SNPs [136].  
Linkage analysis is a kind of study that aims to find the linkage between multiple genes. 
Generally, it is the tendency of genes to be inherited together because of their location near one 
another in the same chromosome [137]. In linkage analysis studies, researchers investigate and 
genotype the genetic variations that are spread throughout the genome in sets of family members 
in order to assess the co-segregation of alleles at any of these polymorphic variations with the 
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disease of interest [138]. Linkage analysis is a powerful analytical method for the discovery of 
genes associated with diseases [139].  Currently, linkage analysis is emerging as a useful method 
for the identification of rare variations associated with complex diseases. It also provides 
statistical evidence of the association between a genetic variation and a disease of interest. 
2.2.4 Genetic variations and drugs (pharmacogenomic analysis) 
Pharmacogenomic analysis is a new field of medicine that focuses on tailoring drug treatment 
based on individual genetic profiling. Pharmacogenomic analysis aims to improve patients’ 
responses to drugs through the study of associations with human genetic variations. The ultimate 
goal of pharmacogenomics is to build some predictive models that use patients’ genotypes to 
improve the treatment effectiveness and reduce the adverse effects of drugs [140]. The US Food 
and Drug Administration (FDA) produced a number of drug label revisions in order to include 
some relevant pharmacogenomic information. However, clinical adoption of pharmacogenomics 
is still slow [141]. Examples of important applications of pharmacogenomics that have been 
approved by the FDA [142] include warfarin and CYP2C9/VKORC1, abacavir and HLA-
B*5701, HLA-B*1502, and TPMT. 
In general, drugs are tested on large populations, and average individual response is 
reported. On the other hand, personalized medicine argues that every patient has a different 
response to a specific drug. Thus, if a genetic variation in a patient is associated with a specific 
drug response, then clinicians can use this information to make some clinical decisions such as 
adjusting the dose or changing the drug. Two important factors should be taken into account 
when studying an individual’s response to a specific drug [143]: 1) how much of the drug is 
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required to reach its goal in the body? and 2) how well do the individual cells respond to the 
drug? 
Despite the promising future of pharmacogenomic applications in clinical practice, there 
are several challenges [142, 144, 145] such as reimbursement, regulations, the need to educate 
and train health care providers, and the need to improve the health information infrastructure.  
2.2.4.1 PharmGKB 
Information about gene-drug interaction can be found in databases such as DrugBank 
[146] and The Therapeutic Target Database (TTD) [147, 148]. However, only The 
Pharmacogenomics Knowledgebase (PharmGKB) [149, 150] contains information about how 
human genetic variation leads to variation in drug response and drug pathways [151]. 
PharmGKB provides information about variation annotations, drug-centered pathway, 
pharmacogene summaries, clinical annotations, drug-dosing guidelines, and drug labels [152].  
2.3 GENETIC VARIATIONS DATA MANAGEMENT 
The goal of The Human Genome Project was to sequence the whole human genome and to 
identify genetic variations that are associated with diseases [153]. The information about the 
association between genetic variations and diseases is highly related to physicians. However, this 
information is very complex and inaccessible to physicians. Thus, there is a need for 
management systems that can integrate the diverse sets of genetic data and make them easily 
available and accessible to researchers and physicians. 
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The basic functionalities of a data management strategy include [8] 1) data collection, 
which maintains storage and protects security; 2) data integration, which requires the use of 
either standardization or metadata (systematic description of data) in order to make the data 
comparable; and 3) data delivery by making the data available and accessible. By applying these 
data management functions to personal genomic data, we can conclude that the goal of personal 
genomic information management is to collect and integrate different types of genomic data and 
organize them into a structured format (such as a database) that is convenient to use, access, and 
share [1]. Data can be stored in a core database that can be used by custom applications to 
prepare internal reports and statistics, and perform other functions that are specific to the 
research [9] or the clinical practice. Personal genomic information management systems allow 
individuals to share their genomic information with authorized physicians in order to help them 
in making an accurate decisions and personalized treatment options [11-13]. 
One simple approach for managing genetic variations data is the direct code manipulation 
of raw data files, where users can directly extract genetic variations data from a file, perform 
some necessary transformations, and write the results to another file [154]. Although this is a 
very simple and easy-to-use approach, it faces the scalability problem, which means that it may 
not be able to process the growing amount of genetic variations data. A number of applications 
have been developed for managing genetic variation data.  
2.3.1 Genetic variation management systems 
GENOME (The Georgia Tech Emory Networked Object Management Environment) is a 
prototype database management system (DBMS) that aims to manage large-scale and complex 
genomic data and to establish a network of researchable data sources [155]. GENOME can 
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integrate diverse sets of human genetic information from multiple data sources and share these 
data across the Internet. The GENOME prototype is set up as a network of data object servers 
that can request objects from any other server based on the object identifier. A GENOME 
browser is tightly associated with one particular GENOME server, which is known as a local or 
home server. Users can establish accounts on that server in order to obtain above-average read 
and write privileges on that server. In GENOME, Structured Query Language (SQL) statements 
can be used to help users in searching their own servers, or other servers that maintain a given 
type of data object. GENOME provides a dynamic interface that is designed to help users in 
formulating their queries. The network of data servers provides a flexible facility for scaling the 
database over many parallel systems. 
SNPpy is open-source software for managing genotype and phenotype data from multiple 
Genome-Wide Association studies (GWAS) [154]. It manages and merges patients’ data with the 
genomic SNP data from multiple studies and provides a powerful framework that facilitates the 
statistical analysis of SNPs data from GWAS. SNPpy consists of two parts; 1) a database to store 
and integrate SNPs data, and 2) a high-level interface to communicate with the database. One 
important feature of SNPpy is the low-level data validation [156], which is performed using the 
relational database that can constrain the columns’ values to a fixed set of values. For example, if 
a record specifies that a patient’s sex is ‘A’ (the only valid sex values are ‘F’ for female and ‘M’ 
for male), then the database will return an error. 
TEAM (Targeted Enrichment Analysis and Management) is a web-based tool with a user 
interface that allows users to define, manage, and analyze panels of genes [157] in an easy-to-use 
environment [158]. The main goal of TEAM is to allow users to detect diagnostic variations 
from the sequencing data. The input data to the system consist of patient’s genomic variations 
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that are predicted in specific genomic regions. These variations are stored in files with the 
standard Variant Calling Format (VCF) [159]. The VCF files contain all the genetic variations 
that are different from the reference genome in the sequence. The entire management of the VCF 
file is done locally and no patient’s sequence data are sent over the internet. TEAM queries 
several disease-related mutation databases, such as HGMD-public [160], ClinVar [117], and 
COSMIC [161], in order to identify known diagnostic mutations about the disease of interest. 
Cordova (Curated Online Reference Database of Variation Annotations) is an open 
source, web-based content management system that maintains a database of genetic variations 
[162]. The primary goal of the system is to help researchers to determine the clinical significance 
of genetic variations. Cordova integrates genetic variations with pathogenicity prediction results 
from popular algorithms. It provides an interface for researchers to review and organize data 
prior to public release. Cordova offers a platform to share reliable genetic variation data for the 
advancement of research. Users can search the database based on a genomic position or by a 
gene. In the term of variation categorization, “pathogenic” represents mutation published in the 
literature as causing disease, and “unknown significance” represents variation reported in dbSNP 
without a disease association. 
SNPLims is an information system that aims to store and manage the SNP genotype data. 
[163]. Data are stored in a relational database. Each individual in the database is annotated with 
three types of data: genotypes, phenotypes, and demographics. SNPLims integrates genotype, 
phenotype, and demographic data from different laboratories. One goal of SNPLims is to 
manage large-scale genotypes for each sample and to manage a large number of samples and 
phenotypes in order to identify candidate genes for the disease of interest. SNPLims calculates 
the statistically significant association of the SNP with any measurable phenotype. The system 
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has been implemented as a client/server application in which users can access the data either 
through a command line client within a Linux server or through a web interface. 
Based on the review of the previous applications for managing genomic data, we can find 
some features to enhance the functionality of any genomic data management system.  Table 3 
provides a list of these features. 
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Table 3. Some features in genomic data management systems 
 Integration Reports 
or 
figures 




GENOME √  √ √  √ 
SNPpy   √ √   
TEAM  √  √ √ √ 
Cordova √ √ √ √ √  
SNPLims √ √  √ √ √ 
 
2.4 GENETIC VARIATIONS DATA ANALYSIS 
2.4.1 Analytical steps for genetic variations data 
After a genome is sequenced, one critically important step is to conduct data analysis. Specific to 
genetic variations, there are three types of analysis [164]: variation identification, variation 
annotation, and variation visualization.  
2.4.1.1 Variation identification 
Variation identification is the process of identifying genetic variations [165]. Different methods 
can be used to discover and identify genetic variations such as [166] population association, 
case-control studies, using genome-wide markers, and DNA resequencing of candidate genes. 
Usually variation identification can be done through the comparison of sequenced genomes with 
the reference human genome (sequence alignment) and the identification of candidate sites at 
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which one or more samples differ from the reference sequence [167]. Variation identification is 
an important part of genome sequence data analysis. It identifies the relationship between 
genotype and phenotype [167], and therefore the results may be used to determine the risk of 
genetic diseases [168].  
Genetic variations can be classified as either common or rare variations. Common 
variations have minor allele frequencies (MAF) greater than 5 percent. On the other hand, rare 
variations can be only found in a small fraction of sequenced samples and have MAF in the 
range of [0.1% to 2–3%] [169]. It is difficult to identify all variations since most of these 
variations are rare with population frequencies less than 1% [170]. To better understand these 
rare variations, more genome-wide association studies are required to examine these rare 
variations [171].  
There are several tools for variation identification. However, there is no single tool that 
can identify all genetic variations [172]. This means that multiple tools need to be applied 
together. CRISP (Comprehensive Read Analysis for Identification of Single Nucleotide 
Polymorphisms (SNPs) from Pooled Sequencing) is a software program designed to detect SNPs 
and short INDELs from high-throughput sequencing of pooled DNA samples [173]. CRISP can 
detect both rare and common variations [174].  
2.4.1.2 Variation annotation 
Variation annotation refers to the classification and prediction of the functional impact of 
variations, and then filtering and prioritizing the ones that cause diseases [175]. Several tools are 
available for variation annotations such as ANNOVAR, VEP, and SVA. ANNOVAR is a 
command-line tool that provides functional annotation of single nucleotide variations (SNVs), 
INDELs, and CNVs [164]. ANNOVAR examines the variations’ functional consequence on 
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genes, reports functional importance scores, and identifies variations reported in the 1000 
Genomes Project and dbSNP [176]. VEP (Variation Effect Predictor) is available as a web-based 
tool that can be used to analyze up to 750 variations each time, as well as a downloadable script 
that can be used to analyze larger data sets [177]. SVA (Sequence Variation Analyzer) is a 
software program that provides a predicted biological function of the variations identified in the 
next-generation sequencing studies [178]. SVA allows visualization of the variations in the 
corresponding sequences by using a specified browser. 
2.4.1.3 Variation visualization 
Variation visualization refers to the validation and visual representation of genetic variations 
[179]. IGV (The Integrative Genomics Viewer) is a lightweight tool that supports the integration 
with clinical and phenotypic data [180]. IGV allows users to explore large-scale genomic data 
sets. IGV allows users to zoom in and out through the genome at any level of detail, up to a 
single base [181]. UCSC Genome Browser [182] is a web-based graphical viewer of genome 
sequences. It provides genome annotations and disease annotations [183] at various levels of 
detail, from base-pair level to chromosome level. Figure 4 shows visualization of a DNA 
sequence including genetic variations. 
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Figure 4. UCSC Visualization 
2.4.2 Genetic variation analysis systems  
The Genomes Management Application (GEM.app) is a set of tools that facilitate the storage, 
annotation, and analysis of genetic variation data. The goal of GEM.app is to manage, visualize, 
and analyze large genomic data sets [184]. GEM.app allows researchers to share data and 
perform joint analysis using an automated pipeline. GEM.app provides a powerful and user- 
friendly analysis and interpretation. The system is fast and can obtain results within 4 seconds 
across ~1,200 exomes. GEM.app is a web-based application [185] that makes genomic data 
available and accessible to researchers. One disadvantage of GEM.app is that it doesn’t provide 
analysis of large chromosomal structural variations, large INDELs, or CNVs [185]. GEM.app 
has a flexible graphical user interface that is implemented in layers to facilitate efficient handling 
and querying of data. GEM.app framework has been used to identify clinically relevant 
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variations in a number of disorders such as inherited deafness, Charcot–Marie–Tooth (CMT) 
disease, and dilated cardiomyopathies [186, 187]. It also has been applied to identify novel genes 
[188].  
VAAST (the Variation Annotation, Analysis and Search Tool) is an integrative and a 
probabilistic search tool that ranks DNA variations based on clinical gene importance [189]. This 
software is designed to screen individual genome sequences for clinically significant mutations. 
VAAST takes a sequence, runs it against a background database, and determines how dissimilar 
the sequence is to the sequences in the database. VAAST compares variations from a patient 
against hundreds of healthy genomes, and automatically scores the mutations in the form of a 
gene-by-gene ranking summary. It can identify both common and rare disease-causing variations 
[190]. VAAST evaluates the likelihood of observing the aggregate genotype of a feature given a 
background data set of control genomes. VAAST uses a generalized feature-based prioritization 
approach, which aggregates variations to achieve greater statistical search power. It also provides 
a statistically powerful means to rapidly search personal genome data for damaged genes and 
disease-causing variations. VAAST can score both coding and non-coding variations, and 
evaluate the aggregative impact of both types of SNVs simultaneously. One limitation of this 
tool is that it is not intended for browsing of variation and annotation data [184]. 
GenePattern provides a web-based interface that allows users to access a huge array of 
computational tools for genomic data analysis [191] such as gene expression analysis [192], 
proteomics analysis,  RNA-seq analysis, and SNP analysis. GenePattern includes multiple user 
interfaces, including a web browser, application, and programmatic interfaces to make analysis 
modules and pipelines available to a broad range of users. One problem in GenePattern is that 
the Java client doesn’t always find the newly created modules or pipelines in the web 
 35 
application. GenePattern provides access to more than 220 genomic analysis tools. It uses the 
analysis tools as building blocks to design sophisticated analysis pipelines. 
Gemini (GENome MINing) is a software package for annotating and exploring genetic 
variations identified by large-scale whole-genome and whole-exome sequencing studies [193]. 
Gemini provides researchers with a standard framework for personal and medical genomics. 
Gemini integrates all forms of genetic variation (i.e., SNPs, INDELs, and structural variations) 
with diverse genome annotations databases such as dbSNP, ENCODE, UCSC, and ClinVar into 
a single database. When variations are uploaded, GEMINI automatically annotates them with 
pre-installed annotations gathered from resources such as dbSNP and ClinVar. GEMINI stores 
the annotated variations in a SQL database where researchers can query variations based on 
criteria such as sample genotypes and inheritance patterns. It also provides mechanisms for ad 
hoc queries and data exploration. The end result of the process is a database that researchers can 
query to identify variations based on the annotations or the genotypes of specific samples being 
studied. The architecture of GEMINI is shown in Figure 5. 
 
Figure 5. Architecture of GEMINI 
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VarSifter is a graphical software program designed to display, sort, filter, and sift 
variation data from parallel sequencing experiments [194]. This tool offers simple and user- 
friendly analyses and visualization of the extensive amount of data produced by exome 
sequencing. Researchers can view exome-scale sequence variation and perform sorting, filtering, 
and searching required to analyze these data for biological relevance. VarSifter is able to assist in 
the discovery of important variations linked with human disease [195, 196]. One limitation of 
VarSifter is that it is designed for a desktop computer and can only manage a modest amount of 
data [184]. 
VAR-MD is a software tool that analyzes genetic variations derived from exome 
sequencing in human pedigrees with Mendelian inheritance. VAR-MD produces a ranked list of 
potential disease-causing variations based on factors such as predicted pathogenicity, Mendelian 
inheritance models, genotype quality, and population variation frequency data. VAR-MD 
facilitates the diagnosis of rare diseases by improving the speed and accuracy of exome 
sequencing data analysis. This tool is unique as it uses family-based annotation of sequence data 
to enhance mutation identification [197]. VAR-MD implements a stepwise filtering algorithm to 
exclude variations identified as having a low potential to be disease-causing genotypes or a high 
potential to be false-positive genotypes. One limitation of VAR-MD is that it can work with 
small and simple pedigrees and a defined group of genetic models. It can’t perform as expected 
if there is genetic heterogeneity or incomplete phenotyping. Another limitation is that it can’t 
incorporate data from half-siblings and other “nonnuclear” pedigree members. Figure 6 shows 
the flow of information in VAR-MD system. Table 4 provides a comparison between the 




Figure 6. Flow of Information in VAR-MD System 
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Table 4. Comparisons between genetic variations data analysis systems 
System Advantages Limitations 
GEM.app • Efficient for managing large genome data 
sets. 
• User-friendly analysis. 
• Users don’t need to have computational 
experiences. 
• Simplicity and speed. 
• Bioinformatics skills are not required. 
• Secure data transmission. 
It doesn’t provide analysis of large 
chromosomal structural variations, large 
insertions/deletions, or copy-number 
variations. 
VAAST • Ranking the DNA variants based on 
clinical gene importance in an automatic 
way. 
• Identifying both common and rare disease-
causing variants. 
It is not intended for the browsing of 
variant and annotation data. 
GenePattern • Supporting a broad community of users at 
all levels of computational experience. 
• Allowing users to access a large array of 
computational tools (modules). 
Java client doesn’t always find the 
newly created modules or pipelines in 
the web application. 
Gemini • Annotating and exploring genetic 
variations. 
• Working as a standalone genome analysis 
toolkit and as a framework to build 
sophisticated graphical analysis and 
visualization tools. 
• GEMINI allows researchers to compose 
complex queries based on sample 
genotypes. 
• The extensive time and resources 
required to import a VCF file and 
associated annotations into the 
GEMINI database. 
VarSifter • Offering a simple and user-friendly 
analyses and visualization of the huge 
amount of data produced by exome 
sequencing. 
• Can be used by researchers with any level 
of computational skills. 
• Able to assist in the discovery of important 
variants linked with human diseases. 
• It is designed for  desktop 
computers and can only manage a 
modest amount of data 
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Table 4 (Continued) 
VAR-MD • Producing a ranked list of potential 
disease-causing variants. 
• Facilitating the diagnosis of rare diseases. 
• Using family-based annotation of 
sequence data to enhance mutation 
identification. 
• VAR-MD can work with small 
simple pedigrees and a defined 
group of genetic models. It doesn’t 
perform as expected if there is 
genetic heterogeneity or incomplete 
phenotyping.  
• VAR-MD can’t incorporate data 
from half-siblings and other 
“nonnuclear” pedigree members. 
 
2.5 CONCLUSION OF LITERATURE REVIEW 
Today, the study of personal genomic data is a key step toward the predictive medicine where 
the individual’s genetic profile can be used to predict the best treatment options. Basic 
challenges with genetic variations data include 1) terminology is not standardized, meaning 
variations can be referred to as mutations, polymorphisms, or SNPs. Additionally, variation 
effects can be called pathogenic, deleterious, or disease-associated; 2) most variations are rare, 
which means that it’s hard to discover and identify these variations; and 3) lack of 
standardization of the functional impact of genetic variations. More specifically, the literature 
contains many papers about one disease, and their results do not necessarily agree with one 
another. Thus, it would be difficult to determine which variations are significantly applicable to 
the patient. 
Due to the availability of whole genome information, researchers have a much clearer 
understanding of the complete set of human genes and genetic variations. Now we can claim that 
most human diseases have genetic components [198], either inherited mutations from the parents 
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or de novo mutations in some individuals. However, the relationship between genetic variations 
and diseases is not that simple; we can’t ensure that a person may develop a specific disease 
because he/she has the related genetic variation.  Many challenges face the analysis of genetic 
variations data: tools are not readily available for biomedical researchers, tools are difficult to 
use, and results are difficult to interpret correctly. 
Based on this review, we can find that there are few systems for managing and analyzing 
genetic variation data that are currently in use for research purposes. This brings us to the need 
for further research in the field of managing and analyzing genetic variation data to support 
clinical practice. HIM professionals have the basic skills to manage large-scale data, they just 
need education in the field of genomics to be able to understand these genomic data and pass 
them to genomic data analysis tools in order to provide some summary results to physicians. 
Thus, HIM professionals can play a key role in developing such systems for managing and 
analyzing large-scale genomic data and make these data available and easily accessible. 
As a conclusion, the success in integrating genomic data within clinical practices and the 
implementation of personalized medicine depends on the ability to analyze the scalable amount 
of genetic variation data and the ability to integrate these genomic data with the available 
personal data. Performance, searchability, security, and scalability are key features that should be 
taken into consideration when designing a genomic data management and analysis system.  
One suggested solution is to create an integrated database for clinical use. This database 
should be able to organize all the relevant information for each disease in one place and present 
the information in an easy-to-understand format. When the information is needed, it can be 
retrieved immediately in a single step, instead of requiring healthcare providers to come up with 
a data analysis procedure to query and combine pieces of information from multiple places. In 
 41 
other words, an integrated and comprehensive genomic information management and analysis 
system for clinical use is necessary. 
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3.0  METHODOLOGY 
This chapter discusses the specific aims of this research, the design, and research methods for 
each one of the specific aims. 
3.1 SPECIFIC AIMS 
This study aims to manage and analyze large amounts of genomic data and to enable convenient 
extraction of information for physicians. These aims can be achieved as follows: 
Specific Aim 1: To determine, via a survey, the current status of physicians in using genomic 
data in their clinical practices, and their expectations about the features and characteristics of a 
genomic information system to support their clinical practices. 
Research Hypothesis 1: This survey addresses two issues: first, whether physicians are able to, 
are currently using, or want to use genomics in their clinical practices; secondly, understanding 
physicians’ expectations about the features and characteristics of a genomic information system. 
Specific Aim 2: To develop a system that manages personal genomic data, such as genetic 
variation data, through the following steps: collecting data from multiple sources, extracting 
information, and integrating these data into a structured format in a central database. 
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Research Hypothesis 2: The system provides one single place for various types of genomic 
information needed by physicians, so that they can conveniently access the desired patient 
genetic information and current research results in one place.  
Specific Aim 3: To develop data analysis algorithms and combine them with the data 
management system. These data analysis algorithms analyze complex personal genomic data 
through the following steps: identifying the genetic information related to a certain disease, 
analyzing VCF files, identifying patients’ genetic variations related to the disease of interest, and 
identifying the corresponding pharmacogenomic information.  
Research Hypothesis 3:  The system, through the data analysis algorithms, allows physicians to 
screen and analyze all the genetic variations in the patient and then identify the genetic variations 
associated with the disease of interest. The system identifies the clinical significance of every 
single genetic variation in the patient. It also identifies the corresponding pharmacogenomic 
information for each patient.  
Specific Aim 4: To generate user-friendly summary reports for physicians. These reports are 
well-formatted reports and provide a summary of genomic findings. 
Research Hypothesis 4: The generated reports are easily understood by physicians. They 
include information about the patient genetic variations related to a certain disease and the 
corresponding pharmacogenomic information. Therefore, physicians can conveniently identify 
the genetic reasons for diseases and determine personalized treatment options based on the 
information provided in the report. 
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3.2 SPECIFIC AIM 1: SURVEY OF PHYSICIANS’ NEEDS AND EXPECTATIONS 
3.2.1 Theoretical framework 
The survey was developed according to the Rogers Diffusion of Innovation (DOI) theory [199]. 
Rogers defines an innovation as a practice that can be perceived as new. Applying genomics into 
clinical practice meets Rogers’ definition of innovation [200, 201]. According to the DOI theory, 
diffusion of innovation is led by a set of innovators who familiarize themselves with the 
innovation (knowledge), form attitudes about the potential of innovation to improve the current 
practice (attitudes/receptivity), decide whether to adopt the new practice (decision), and evaluate 
the adopted practice (confidence). In this survey, there are four different sections corresponding 
to these four domains: knowledge, attitudes/receptivity, decision, and confidence. Table 5 shows 
the conceptual and operational definitions for each of the domains in the DOI theory and 
corresponding sections in this survey. 
Table 5. Conceptual and operational definitions of DOI theory 
Domain 
(Rogers, 2003) 
Conceptual Definition (Rogers, 
2003) 
Operational Definition Survey Instrument 
Sections 
Knowledge Recognition of the innovation and 
evidence of understanding its 
function. 
Knowledge of applying 




Confidence Level of certainty that knowledge 
about the innovation is accurate. 
Confidence in: new 
findings in genomics, 
motivations of using 
genomics in clinical 
practice, and benefits and 
limitations of genetic tests. 
General opinions 
Attitudes The relative advantage offered by 
the innovations, and the 
recognized need for the 
innovation. 
Perceived advantage and 
disadvantages of 
integrating genomics into 
clinical practice. 
Expected features 




Table 5 (Continued) 
Decision/ 
adoption 
Observation of use of the 
innovation. 
Utilization of using 





A 31-question survey was developed and informed by relevant literature review. Theories and 
findings from a number of studies have been used to guide the selection of the questions in each 
section of the survey. Each question in the survey was reviewed to determine how well it 
measures the DOI domains and meets the survey goals. (Survey questions are provided in 
Appendix A.) 
The survey has five sections: 1) the general information section is about physicians’ basic 
information such as gender, age range, field of practice, and years of experience in the clinical 
practice; 2) the knowledge in genomics section corresponds to the knowledge domain of the DOI 
theory; 3) the general opinions section is about using genomics in the clinical practice and 
whether the physicians believe that applying genomics in a clinical practice can improve the 
quality of their practice. This section corresponds to the confidence domain of the DOI theory; 4) 
the specific tests section assesses physicians’ willingness to order simple genetic tests for single 
gene disorders and sophisticated tests for multiple gene disorders. This section corresponds to the 
decision/adoption domain of the DOI theory; and 5) the expected features of a genomic 
information system section that assesses physicians’ expectations to a desired genomic 
information system. This section corresponds to the attitude domain of the DOI theory. 
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A five-point Likert scale rating level of agreement and familiarity was used to assess 
opinions. Categorical response options were used in the background and general opinion 
questions. The survey was hosted online using Pitt’s Qualtrics system. No personally identifiable 
information (such as name or address of the respondent) was collected in this study. All the 
collected data were kept anonymous. 
3.2.3 Sample and recruitment 
This survey was given to a sample of physicians who work at the University of Pittsburgh. The 
subject selection criteria include: 1) physicians who have at least a few years of clinical practice; 
2) their ages range between 30 and 65; and 3) physicians who are fluent in English. The study 
protocol was reviewed and approved by the University of Pittsburgh Institutional Review Board 
(IRB #: PRO14070123). The study was considered to be exempt because respondents were 
anonymous and there was no risk to participants. 
3.2.4 Statistical analysis 
Respondents’ answers to those survey questions were downloaded from the Qualtrics system and 
exported to SPSS (version 23). All survey results were tabulated and analyzed using descriptive 
statistics. Open-ended questions were summarized separately. 
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3.2.5 Survey validity 
Each survey question was reviewed for content validity by four experts from relevant fields: 
public health, computational genomics, human genetics, and medicine. The reviewers were 
asked to rate the relevancy of each question relative to the study aims. A four-point score was 
used to determine their opinions in terms of relevancy (1: totally irrelevant, 2: somewhat not 
relevant, 3: somewhat relevant, and 4: highly relevant). In the first round of content validity 
review, three questions were regarded as irrelevant questions by two reviewers. These questions 
were about physicians’ overall knowledge in genomics, whether they have ordered any genomic 
tests, and the genetic tests they have ordered in the past. These three questions are highly 
relevant to the study aims. We therefore discussed this with the two reviewers and they agreed 
with our opinion. In other words, all 31 questions in the survey are considered as relevant by all 
four reviewers. The four reviewers also evaluated and commented on the clarity of each question 
in the survey. They pointed out that the clarity level of several questions was not high. We 
changed the wording of those questions. In the second round of the content validity review, all 
four reviewers agreed that all of the survey questions are relevant and clear.  
3.3 SPECIFIC AIM 2: MANAGEMENT  
3.3.1 Theoretical framework 
Theories and findings from a number of studies were used to guide the design of the 
management system. The framework of Parsons et al. for managing diverse, distributed, and 
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heterogeneous scientific data [202] was used to guide the management of the heterogeneous and 
diverse types of genomic data stored in the system. The framework emphasizes the need for 
continued adaptation by technology and people. It also uses some simple terms to describe the 
data such as discoverable, linked, useful, and safe. Table 6 reviews the conceptual and 
operational definitions of the framework terms. 
Table 6. Conceptual and operational definitions of Parsons et al. framework 
Terms  Conceptual Definition  Operational Definition  
Discoverable  Data should be identified and assessed 
using simple tools available to the 
community. 
Physicians can search the system by entering a key 
or a specific word in order to get the desired answer 
for their question. 
Linked Data should be interrelated and 
connected. 
In our system we integrate data from multiple 
databases, combine them in a single place, and make 
them available to physicians. 
Useful  Data should be used in different 
applications, by researchers and decision 
makers. 
Our system can be used by different people, 
including physicians and researchers to get useful 
information.  
Safe  Security, privacy, and confidentiality of 
the data should be taken into 
consideration. 
There will be a number of security measures such as 
role-based access control, user authentication 
processes, and encryption. 
 
The computational framework to integrate biomolecular and clinical data within a 
translational approach [203] was used to guide the design of the basic levels of the management 
system. The framework uses different levels to represent and manage the data. Our system has 
three basic tiers: 1) a data tier that stores information about genes, SNPs, diseases, GWAS, and 
pharmacogenomic information; 2) an application tier that uses Python scripts and Java codes to 
create, update, retrieve, and manage information in the database; and 3) a user interface tier that 
uses Java frames to facilitate the interactions between the user and the system. Figure 7 shows 
the basic tiers of the system. The relational data model was used to organize the data in an 
integrated way in the database [204]. Our system uses MySQL database to store data about 
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genes, SNPs, diseases, GWAS, and pharmacogenomic information. These data can be easily 
retrieved using SQL queries. 
 
Figure 7. Basic Tiers of Our System 
3.3.2 Design 
Our system is designed to be used by physicians in their clinical practices, which means that the 
system should be easy to use and fast since physicians need the desired information readily 
accessible for the patient care purposes. Python scripts are used to search multiple sources and 
obtain all the needed information. These sources include OMIM, dbSNP, ClinVar, GenBank, 
GWAS catalog, and PharmGKB. The obtained information is stored in a MySQL database.  
Our system provides a single place for various types of information needed by physicians 
in personalized medicine practice. In order to meet the system’s design requirements, the system 
has the following essential features: 
• The system is convenient to use. It collects data from multiple sources and organizes 
them into a structured format in the database. For example, the physician enters a patient 
ID and a disease name in the search area of the system, and then the system automatically 
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performs database queries and provides the physician with a report that includes 
information about the patient’s genetic variations that are related to the given disease. 
•  The system precalculates all of the computationally intensive steps for every patient. In 
the clinical environment, physicians don’t have time to wait. They need to get the results 
shortly after they input the request for patient care purposes. Therefore, it’s important for 
the system to precalculate and save the analysis results into the central database. This 
precalculation feature saves a lot of time and helps the physicians to obtain their needed 
information and make their decisions in a timely manner (details are provided in the data 
analysis part). 
• The system provides a number of security measures, including encryption, user 
authentication processes, and role-based access control. Furthermore, the central database 
is not accessible to the public and physicians are not allowed to insert data into the 
database. Dropdown lists are used to make selections. 
3.4 SPECIFIC AIM 3: DATA ANALYSIS  
3.4.1 Theoretical framework 
The Sadedin et al. [205] study was used to guide the design of the analysis part of the system. 
The study identifies three basic requirements for a clinical bioinformatics analysis system: First, 
a clinical system should be designed with a robust and reproducible analysis. Second, genetic 
variations need to be assessed for their relevance to a given patient. Third, the overall flow of the 
analysis should be easy to understand and modify. 
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3.4.2 Design 
Data analysis algorithms were created using Python scripts and Java codes. These algorithms aim 
to screen and analyze all the genetic variations in the patient and then identify the genetic 
variations associated with the disease of interest. The algorithms also identify the corresponding 
pharmacogenomic information for every patient. Data analysis is divided into four steps: (Details 
are provided in the implementation part.)  
• Identifying the genetic information related to a certain disease.  
• Analyzing VCF files.  
• Identifying the patients’ genetic variations related to the given disease. 
• Identifying the related pharmacogenomic information. 
3.5 SPECIFIC AIM 4: REPORT GENERATION 
3.5.1 Theoretical framework  
The design of the generated reports was guided by well-tested practices published in the 
literature [206, 207].  These studies provide some reporting approaches for communicating 
genomic findings relevant to clinical practice. Based on these studies, genomic reports should be 
well-formatted in order to provide a summary of genomic findings. These genomic findings 
enable physicians to take appropriate steps for disease diagnosis, prevention, and management 
for their patients. The studies also emphasize the power of user-friendly reports in reducing the 
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time required to explain test results, leaving more time for discussing the significance of the 
results for patients’ care. 
3.5.2 Design 
The generated reports include four sections: (Details are provided in the implementation part.) 
1) Patient’s information 
2) Result summary 
4) Disease information 
5) Pharmacogenomic information 
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4.0  IMPLEMENTATION 
This chapter discusses the basic functionalities of our system and the security measures in the 
system. 
4.1 SYSTEM FUNCTIONALITIES  
The basic functionalities of the system include data collection, data integration, data analysis, 
and information delivery. 
4.1.1 Data collection 
The system collects data from multiple databases, including GenBank, dbSNP, ClinVar, OMIM, 
GWAS catalog, and PharmGKB. Python scripts were created to extract the required information 
from these heterogeneous data sources. Due to the variable nature of genomic data and the 
rapidly updating data sources, the data extraction scripts will be updated as needed. The system 
collects different types of genomic data from these data sources. The following subsections 
provide some examples of the collected data items.  
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4.1.1.1 Gene information 
GenBank is a comprehensive database that contains publicly available nucleotide sequences and 
their protein translations for several organisms. These sequences are obtained through 
submissions from individual laboratories or batch submissions from large-scale sequencing 
projects [208]. 
A Python script was created and used to process and then extract gene information from 
the GenBank ftp site [209]. In this project our focus is on human genes. Thus, we only extracted 
GenBank files that are related to the human organism (Homo sapiens).  As of December 2015, 
we obtained 49 GenBank files related to the human organism. These files are named “gbpri1 
through gbpri49.” Their sizes range from 47 MB to 245 MB.  Examples of the extracted gene’s 
information include gene symbols, aliases, chromosomes, and citations from PubMed. 
4.1.1.2 Genetic variation information 
Genetic variation information was extracted from both ClinVar and dbSNP databases.  This 
project is primarily focused on the analysis of SNPs. Thus, a Python script was created and used 
to process and then extract the needed SNP’s information from the ClinVar ftp site [210]. 
Examples of the extracted information include variation name, gene symbol, dbSNP ID, and 
clinical significance. This version of the system includes SNPs from two assemblies; GRCh37 
and GRCh38. However, the results showed that some of the extracted SNPs from ClinVar 
missed useful details such as gene details. Therefore, the dbSNP database was used to extract the 
missing information. dbSNP ID was extracted and used to uniquely identify every SNP.  
In the second step, a Python script was created and used to process and then extract the 
needed SNP’s information from the dbSNP ftp site [211]. In this project, our focus is human 
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SNPs. Thus, we only extracted the information about human SNPs. In the dbSNP ftp site, human 
SNPs’ information is arranged into files based on the chromosome number, in which each file 
belongs to one chromosome and contains information about all of the genetic variations in this 
chromosome. This version of the system includes SNPs from two assemblies of build (b144); 
b144_GRCh37p13 and b144_GRCh38p2. Examples of the extracted information include dbSNP 
ID, gene symbol, SNP position in the chromosome, and clinical significance.  
4.1.1.3 Disease information 
Disease information was extracted from the OMIM database. A download request was submitted 
to Johns Hopkins University in order to get access to the OMIM ftp and extract the needed 
information about human diseases. After getting access, a Python script was created to process 
the OMIM data and extract the needed disease’s information. Examples of the extracted 
information include disease name, chromosome number, gene symbol, and dbSNP ID.  
4.1.1.4 GWAS information 
The GWAS catalog [136] was created by using text mining algorithms to extract information 
from all of the published GWAS research articles. A python script was created and used to 
process the GWAS catalog data [212] and then extract the needed information, such as study ID, 
journal information, disease name, dbSNP ID, and chromosome number. 
4.1.1.5 Pharmacogenomic information 
PharmGKB includes more than 26,000 genes. Only a few of them have an impact on disease or 
drug response [150, 151]. In our research project, only those genes in which a variant exists in 
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the PharmGKB variant and clinical annotation files, specifically variant-phenotype-annotation, 
are considered to be gold-standard pharmacogenomic information to which all patients’ genetic 
variations are compared. 
The variant-phenotype-annotation file contains associations in which the variant affects a 
phenotype, with or without drug information [213]. A Python script was created and used to 
process the file and then extract and integrate all of the related information about the 
pharmacogenomic associations.  As a result, for each SNP, the script integrates all of the 
available information about the association between a SNP and a specific disease or drug. 
4.1.2 Data integration 
After collecting data from multiple sources, the system organizes the data into a structured 
format in a central database. The system uses the MySQL relational database to store the 
different types of genomic data, such as genes, genetic variations, diseases, GWAS results, and 
pharmacogenomic associations into database tables. These tables have common fields such as 
gene symbol and variation ID (dbSNP ID). The system uses these common fields to create 
relationships among the tables and link them together. SQL statements can be created to 
manipulate the data in the database. The following subsection illustrates the fields in the database 
tables. 
4.1.2.1 Database tables 
Tables in the database are divided into two categories: 
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1. Extraction output: This category includes those tables created using Python scripts; the 
data in these tables were collected from multiple sources and integrated into a single 
format. 
2. Analysis output: This category includes those tables created during the system execution 
time using Java codes, such as the table that stores personal genetic variations for each 
patient. The data in these tables depend on the analysis results.  
4.1.2.2 Extraction output tables 
GenBank_database table.  This table stores the data collected from the GenBank database. It 
has a total of 331,770 records. Each record has the following fields: 
• Gene_Symbol, such as CFTR, BRCA. 
• Accession_Number: The unique identifier for the gene in GenBank. 
• Sequence_Length: Number of nucleotide base pairs (or amino acid residues) in the gene 
sequence. 
• Sequence_Type, such as DNA, RNA, mRNA. 
• Chromosome: chromosomal location of this gene. 
• Gene_Synonyms: other synonyms of the gene symbol. 
• PubMed_ID (PubMed Identifier): this ID provides a link to a PubMed paper about this 
gene. 
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ClinVar table. This table stores the data collected from the ClinVar database. It has a total of 
199,054 records. Each record has the following fields: 
• Variant_Type: In this project our focus is on the SNP. Thus, this field has a value of 
Single Nucleotide Polymorphism. 
• Variant_Name: the name of this variant. 
• Gene_Symbol: the symbol of the gene that is overlapping the SNP. 
• Clinical_Significance: the reported clinical significance of this variant such as benign, 
likely benign, or pathogenic. 
• Assembly: the name of the assembly on which locations are based such as GRCh37. 
• dbSNP_ID: the unique identifier of the variant in the dbSNP database. 
• Chromosome: chromosomal location of this variant. 
• Reference_Allele: The allele at the location defined on the reference sequence. 
• Alternative_ Allele: The difference relative to that reference. 
• Disease_OMIM: the identifier of the disease reported for this variant as in OMIM 
database. 
dbSNP_database. This table stores the data collected from the dbSNP database. It has a total of 
105,113 records. Each record has the following fields: 
• dbSNP_ID: the unique identifier of the variant in the dbSNP database. 
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• Chromosome: chromosomal location of this variant. 
• Position: the position of this variant in the chromosome. 
• Gene_Symbol: the gene that is overlapping the SNP. 
• Significance: the reported clinical significance of this variant, including unknown, 
untested, non-pathogenic, probable-non-pathogenic, probable-pathogenic, pathogenic, 
and other. 
OMIM_database. This table stores the data collected from the OMIM database. It has a total of 
6,558 records. Each record has the following fields: 
• Disease_Name: the name of this disorder. 
• Disease_OMIM: the corresponding OMIM ID for this disease. 
• Gene_Symbol: the symbol of the related gene to this disease. 
• Gene_MIM_ID: the corresponding OMIM ID for the reported gene. 
• Chromosome: the related chromosome number of this disease.  
GWAS_Catalog table: This table stores the data collected from the GWAS catalog. It has a 
total of 17,832 records. Each record has the following fields: 
• StudyID: this is the PubMed ID for this GWAS article. 
• dbSNP_ID: the ID of the SNP reported in the GWAS. Multiple SNPs in the same GWAS 
have multiple records in the database.  
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• Chromosome: chromosomal location of the reported SNP. 
• Disease_Name: the name of disease investigated in this GWAS. 
• Gene_Symbol: Gene symbol related to the reported SNP. 
GWAS_Study_Info. This table stores information about each GWAS article. It has a total of 
2,149 records. Each record has the following fields: 
• Study_ID: this is the PubMed ID for this GWAS article. 
• Date_Addded_to_Catalog: when this GWAS was added to the catalog. 
• Journal: the name of the journal that published this GWAS. 
• Sample_Info: sample size in this GWAS. 
• Population: the population studied in this GWAS. 
Variant_Citation table: Each record in this table stores a PubMed ID that links to a paper about 
a specific SNP. These data were extracted from the ClinVar database using a Python script. The 
table has a total of 101,186 records. Each record has the following fields: 
• dbSNP_ID: the unique identifier of the variant in the dbSNP database. 
• PubMed_ID: this ID provides a link to a PubMed paper about this SNP. 
Pharmacogenomics table: This table is created based on the information extracted and 
integrated from the PharmGKB variant-phenotype-annotation file. The table has a total of 3,602 
records. Each record has the following fields:  
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• dbSNP_ID: the unique identifier of the variant in the dbSNP database. 
• Gene_Symbol: related gene symbol. 
• Drug: drug name. 
• PubMed_ID: this ID links to the corresponding article in PubMed. 
• Category: options include efficacy, toxicity, dosage, or other. 
• Significance: yes or no, based on the significance of the association, such as the 
association between a SNP and a specific drug, or the association between a SNP and a 
specific disease [213]. 
• Recommendations: one sentence represents the association between the given variant and 
one disease or between the given variant and one drug [213].  
4.1.3 Data analysis 
Data analysis is divided into four steps: identifying the genetic information related to a certain 
disease; analyzing VCF files; identifying the patients’ genetic variations related to the given 
disease; and identifying the corresponding pharmacogenomic information. Algorithms were 
created to perform each step of the data analysis. 
4.1.3.1 Identifying the genetic information related to a certain disease 
The system provides detailed genetic information about a specific disease. When the user enters 
a disease name in the search area, the system searches the OMIM database table and identifies 
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the related records. These OMIM records contain information such as disease name, related 
genes, chromosome number, and OMIM ID. Based on the OMIM ID, the system searches the 
ClinVar database table and returns all of the SNPs related to the disease of interest. Some of the 
returned SNPs from ClinVar don’t have certain desired information such as gene symbol and 
gene ID. In that case, the system searches these SNPs in the dbSNP database table and retrieves 
all of the related information. After these steps are done, the system returns a database table with 
the detailed information related to the disease of interest, including genetic variation name, SNP 
ID, gene symbol, GenBank ID, chromosome number, and the clinical significance of the 
variation (including unknown, untested, non-pathogenic, probable-non-pathogenic, probable-
pathogenic, pathogenic, and other). Additionally, the system searches the given disease name in 
the GWAS catalog table in the database and retrieves all of the related detailed genetic 
information. For every specific disease, all of these data items are stored in the MySQL database. 
4.1.3.2 Analyzing VCF files 
The input of the system is a Variant Call Format (VCF) file. VCF is a standardized text file 
format for representing genetic variations. The VCF file contains one record for every single 
genetic variation in one or a group of patients. There is no identifiable personal information in 
the VCF file.  
In order to analyze the VCF file, the system first determines the number of patients in the 
VCF file, and then processes all of the genetic variations in the VCF. For every variation record, 
the system determines the detailed information, including dbSNP ID, reference allele, alternative 
allele, chromosome, position of the SNP in the chromosome, and the number of copies of the 
genetic variation in each patient. For every patient, the system extracts the genetic variations that 
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have one or more copies. The extracted information from the VCF file is stored in the MySQL 
database. 
4.1.3.3 Identifying patients’ variations related to the given disease  
As shown in Figure 8, the system performs the following steps in order to identify patients’ 
genetic variations related to the disease of interest: 
1) The system identifies the disease of interest and performs all of the steps provided 
previously in the first step of data analysis (identifying the genetic information related to a 
certain disease). 
2) The system then searches the table in the central database that stores all of the detailed 
genetic information of the disease of interest. Based on this table, the system retrieves a list 
of all the pathogenic SNPs that are related to the disease of interest. 
3) The system searches the table in the central database that stores all of the patients’ genetic 
variations that were extracted by analyzing the VCF file. From this table, the system 
identifies the genetic variations related to every patient. As mentioned earlier, these are the 
genetic variations with one or more copies. 
4) The system identifies the chromosome numbers that are related to the disease of interest (the 
chromosome numbers can be retrieved from the OMIM table), the system then retrieves 
patients’ genetic variations in these identified chromosomes. After that, for every genetic 
variation in the patient (only the genetic variations in the identified chromosomes), the 
system compares this genetic variation with all of the genetic variations related to the 
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disease of interest (which were identified in the first step of analysis). The comparison is 
done based on the related dbSNP ID. If this genetic variation matches any of the disease 
related genetic variations, the system then goes deeper and determines the specific alleles in 
this patient. If the alleles are matched between the patient’s genetic variation and the 
disease-related genetic variation, the system then reports that this patient has a pathogenic 
variation related to the disease of interest. The process will be repeated for all of the genetic 
variations in the patient.  
4.1.3.4 Identifying the corresponding pharmacogenomic information 
The system identifies the genetic variations that have pharmacogenomic associations related to 
the disease of interest, pain and anesthesia (this information can be retrieved from the 
pharmacogenomics table in the central database). For every genetic variation in the patient, the 
system compares this genetic variation with all of the previously identified genetic variations that 
have pharmacogenomic associations. The comparison is done based on the related dbSNP ID. If 
this genetic variation matches any one of the genetic variations that have pharmacogenomic 
association, the system then goes deeper and determines the specific alleles in this patient. If the 
alleles are matched between the patient’s genetic variation and the alleles provided in the 
pharmacogenomics table for this specific genetic variation, the system then reports the related 
pharmacogenomic associations with this genetic variation. The process will be repeated for all of 
the genetic variations in the patient.  
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Figure 8. Information Flow in the Data Analysis  
 
The system precalculates all the computationally intensive steps for every patient. For 
example, all four steps of data analysis (analyzing the VCF file, identifying the genetic 
variations, and identifying the related pharmacogenomic information for every patient) are pre-
calculated and the results are stored in the database to be used by physicians.  
4.1.4 Information delivery 
Our system provides a graphical user interface (GUI) to facilitate the communication between 
the user and the system. The users of this system are physicians who may not have a strong 
background in genomics. Therefore, they need reports that are easy to read and understand 
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instead of typical research reports that include extensive details of analytical procedures and 
results. Typically, physicians don’t want to see these data analysis details as long as they are 
convinced that the results from the system are reliable. This is how physicians treat many other 
types of laboratory reports; they do not need to know the specific lab technology or lab 
procedure that is used to obtain the results. 
The system provides a search feature that helps to make the data accessible to physicians 
through simple queries. The system generates user-friendly summary reports after the desired 
information is retrieved from the central database. The generated reports include information 
about the patient’s genetic variations related to the disease of interest. More specifically, the 
report has four sections: 1) patient’s information such as patient ID; 2) result summary started 
with the word ‘positive’ or ‘negative’, which indicates whether the patient has the genetic 
variations related to the given disease; 3) disease information such as, relevant genes, the 
identified patient’s genetic variations, and  links to PubMed papers about the relevant genes and 
genetic variations; and 4) pharmacogenomic information such as information about certain 
medications, possible dosage, and the risk of adverse events in some cases. The report includes a 
link to a help page that provides a brief description of the basic parts of the report. 
4.2 SYSTEM SECURITY 
Based on HIPAA requirements [214-217] for database applications, our system has the following 
security measures:  
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4.2.1 Access control measures  
User’s access to our system is controlled by a set of security measures: 
4.2.1.1 Access to the system  
• Authentication and authorization service access, which means that every user needs to 
login with a unique username and password to gain access; only authorized people can 
access the data.   
• Role-based access control: our system assigns roles to users in order to ensure the 
authorizing access to the data only when such access is appropriate based on the user’s 
role. A role determines what a user is permitted to see and what operations a user can 
perform. For example, users with administrator privileges can access, retrieve, and update 
data. On the other hand, physicians can only view patients’ genomic data without the 
ability to update anything. 
4.2.1.2 Database access  
• The central database is not accessible to the public, and physicians are not allowed to 
insert new information into the database. They can just upload VCF files and view the 
analysis results. Our system provides dropdown lists for selections. Therefore, physicians 
use these dropdown lists for selection.  
• The central database is protected with a secure connection. Only authorized people who 
have a username and password can connect to the database. In our research project, only 
administrators can connect and access the database.  
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4.2.2 Encryption  
The Advanced Encryption Standard (AES) algorithm is used to encrypt patients’ genomic data, 
including patients’ genetic variations, and all extracted information from a VCF file. AES is a 
symmetric block cipher algorithm published by the National Institute of Standards and 
Technology (NIST) in December 2001 [218]. AES uses four types of transformations in order to 
ensure data security, including substitution, permutation, mixing, and key-adding. AES provides 
several key lengths, including 128, 192, and 256. In our system, we used AES-128. This 
algorithm is simple and can be easily implemented with a minimum amount of memory and 
relatively low storage and hardware requirements. In the case of key transmission, the public key 
cryptography will be  used to transmit the AES encryption key [219, 220]. 
 69 
5.0  RESULTS  
This chapter discusses the results of our survey study about physicians’ needs and expectations, 
as well as the results of our system. 
5.1 THE SURVEY OF PHYSICIANS’ NEEDS AND EXPECTATIONS 
5.1.1 Study population 
A total of 15 individual responses from physicians at the University of Pittsburgh were obtained. 
The participating physicians ranged in age from 31 to more than 60 years old. They were mostly 
male (80%). A large portion of the physicians have more than 30 years of experience in medical 
practice (40%).  
5.1.2 Knowledge in genomics 
As shown in Figure 9, forty percent (40%) of the participating physicians reported that they are 
quite familiar with genomics terms and genetic tests. Thirteen percent (13.33%) have an 
extensive knowledge in genomics. Twenty percent (20%) claimed to be experts in the field of 
genomics and felt highly confident in their abilities to deal with genomic information. 
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Figure 9. Overall Knowledge in Genomics 
 
Figure 10 shows that seventy three percent (73.33%) of the participating physicians 
reported that they agree or strongly agree that enhancing their knowledge in genomics can be 
beneficial to their patients. Other physicians strongly disagreed with this claim. However, one 
needs to note that these respondents strongly disagreed with this claim, not the benefit of 
genomic knowledge to healthcare. After all, if 30 percent of the participating physicians are 
already experts or have an extensive knowledge in genomics, then enhancing their knowledge in 
genomics further will not produce much difference, and in turn, it will not produce additional 
benefits to their patients. 
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Figure 10. Enhancing Knowledge in Genomics 
5.1.3 General opinions 
As shown in Figure 11, the most frequently identified motivations for using genomics in clinical 
practice include (n=15): cancer treatment (26.76%), single gene disorder (20%), and 
pharmacogenomic analysis (20%).  As shown in Figure 12, all of the participating physicians 
believed that new findings in genomics can change and improve the clinical practice (53.33% 
agree, and 46.67% strongly agree, n=15).  
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Figure 11. Motivations of Using Genomics 
 
Figure 12. New Findings in Genomics 
As shown in Figure 13, most of the participating physicians either reported that they 
agree (53.33%, n=15) or strongly agree (33.33%, n=15) that genomics should be incorporated 
into the clinical practice. 
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Figure 13. Incorporating Genomics in Clinical Practice 
5.1.4 Specific genetic tests 
The majority of the participating physicians indicated that they are either very likely to order 
genetic tests for single gene disorders (50%, n=14) or somewhat likely (14.29%, n=14). Twenty-
one percent (21.43%, n=14) reported that they are somewhat unlikely to order genetic tests for 
single gene disorders. The participating physicians had different perspectives toward ordering 
sophisticated genetic tests for multiple gene disorders (38.46% somewhat unlikely, 15.38% 
neutral, 23.08% somewhat likely, 23.08% very likely, n=13).   
The majority of the participating physicians agreed that genomics should be used to guide 
decisions about medication prescription, including dosage for each individual patient (66.67%, 
n=15). Fewer than seven percent (6.67%, n=15) strongly disagreed that genomics should be 
applied in personalized medicine. The majority of participating physicians reported that they 
agree that genomics can predict adverse drug reactions (64.29%, n=14); the rest of the study 
participants were neutral.   
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As shown in Figure 14, the majority of the participating physicians reported that they are 
confident in using genomics for personalized cancer treatment (57.14% somewhat confident, 
35.71% very confident, n=14). Only one physician reported a neutral response toward the using 
of genomics in personalized cancer treatment. 
 
Figure 14. Personalized Cancer Treatment  
  
Physicians have very high standards in terms of the accuracy of the genetic analysis 
results in a clinical report. As shown in Figure 15, sixty-six percent (66.37%, n=15) of the 
participating physicians reported that they can tolerate a small number of errors or uncertainty in 
the report, and twenty percent (20%) reported that they expect an absolutely correct report (no 
error at all in a report, no matter how complicated the tests or analyses can be). 
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Figure 15. Desired Levels of Accuracy of Genetic Analysis Results 
 
Different types of genetic tests were reported by the participating physicians as the most 
frequently ordered tests. Table 7 shows the reported genetic tests and a brief description. 
Table 7. The reported genetic tests 
Gene Testing Disorder Testing  Other Testing  
RAS family members (A family of 
genes that may cause cancer when they 
are mutated. These genes include Kras, 
Hras, and Nras) 




provides a pan 
cancer test for a 
number of genes 
such as BRAF, 
BRCA1, and 
BRCA2) 
BRCA (related to breast cancer) cystic fibrosis WES (Whole 
exome 
sequencing) 
MMR (related to colon cancer) BCR-ABL (the presence of this gene 
sequence confirms the diagnosis of chronic 





Table 7 (Continued) 
PALB2 (related to breast cancer) factor V Leiden (inherited disorder of 
blood clotting) 
 
MUTYH (related to colorectal cancer) prothrombin gene variant 20210 
(prothrombin is a bleeding disorder that 
slows the blood clotting process) 
 
ALK (related to lung cancer) HFE genes for hemochromatosis (a 
disorder that causes the body to absorb too 
much iron from the diet) 
 
p53 (related to breast cancer) HLA-B27 (a blood test to look for a 
protein that is found on the surface of 
white blood cells) 
 
PRSS1 screening (related to hereditary 
pancreatitis) 
alpha-1 anti-trypsin (an inherited disorder 
that may cause lung disease and liver 
disease) 
 
DNA repair gene mutations MSI PCR (which is related to lynch 
syndrome) 
 
 Hereditary gene panels (a test of multiple 
genes panel that identifies an elevated risk 
for important cancers). 
 
 
5.1.5 Expected features from a genomic information system 
Based on the responses to the survey, we identified a set of desired features of a patient genomic 
information system. First, the system needs to be easy to search (93.33%, n=15);  second, the 
information in the system needs to be updated periodically (93.34%, n=15); third, the data in the 
system need to be comprehensive and include complete information about diseases, related 
genetic variations and genes, and pharmacogenomic information (86.66%, n=15); fourth, the 
system needs to be easy to use and interpret results (100%, n=15); fifth, the system needs to be 
convenient to access at any time (100%, n=15); and finally, the system needs to be secure 
(53.33%, n=15). Table 8 lists the desired features of a genomic information system. 
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Table 8. Desired features of a genomic information system 
Desired Features Physicians Percent of Agreement  
Easy to search  93.33% 
Updated periodically 93.34% 
Comprehensive 86.66% 
Easy to use and interpret results 100% 
Convenient to access 100% 
Secure 53.33% 
 
The majority of the participating physicians indicated that they want the genomic report 
to be stored in the EHR along with other patient information (85.71%, n=14). The majority of the 
participating physicians preferred to store the genetic analysis report for more than three years 
(92.86%, n=14). The majority of the participating physicians believed that genomic information 
systems should provide explanations for genomic test results interpretation (85.72%, n=14). 
Table 9 lists physicians’ suggestions for a genomic information system.  
Table 9. Physicians' suggestions for a genomic information system 
Suggestions  Physicians’ Percent of Agreement 
Genomic reports need to be stored in the EHR  85.71% 
Genetic analysis reports need to be stored for 
more than three years. 
92.86% 
Genomic information systems should provide 




As shown in Figure 16, the most frequently identified problems for applying genomics in 
the clinical practice include the usefulness of the genetic analysis result to physicians’ treatment 
plan (53.33%, n=15) and insurance coverage for genetic tests (13.33%, n=15). 
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Figure 16. Problems of Applying Genomics in Clinical Practice 
5.2 SYSTEM RESULTS 
5.2.1 System data 
Our system is mainly focused on the analysis of SNPs, which are the most common type of 
genetic variations in the human genome [74]. Thus, the system can screen and analyze all human 
SNPs available in ClinVar and dbSNP databases. Additionally, the system can search and 
analyze all the diseases available in the OMIM database and GWAS catalog.  
The extraction scripts were re-executed on December 2015 to extract all the needed 
information from OMIM, dbSNP, ClinVar, GWAS catalog, PharmGKB, and GenBank 
databases.  As a result, the current version of the system includes: 
• 6,558 diseases such as Alzheimer’s, Pancreatitis, and Autism.  
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• 199,054 human SNPs from ClinVar and 105,113 human SNPs from dbSNP, such as rs 
150829393, rs 200401432, and rs 111033557. 
• 331,770 human genes such as BRCA1, BRCA2, and PRSS1.  
• 2,320 GWAS articles. 
• 3,602 different pharmacogenomic associations. 
5.2.2 Use case scenario 
In this use case, the system is used to screen the personal genetic variations in 140 patients and to 
identify all of the genetic information related to Pancreatitis. At the beginning, the user needs to 
create an account in the system and then login to the system. Figure 17 shows the sign-up page. 
Figure 18 shows the login page. 
 
Figure 17. Sign-Up Page 
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Figure 18. System Login Page 
 
Then, the user gets into the system home page as shown in Figure 19. This page provides 
links to all of the pages in the system, including search for disease, analyze VCF files, show 
group reports, and show individual reports.  
 
Figure 19. System Home Page 
 
In the “search for disease” page, the user can search for any disease of interest. In this use 
case, the user needs to identify the genetic information associated with “Pancreatitis”. The user 
chooses the disease name from the dropdown list and then hits the button “search”. The system 
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then automatically searches the disease name in the OMIM database table and the GWAS 
catalog table and displays the results into a table as shown in Figure 20. 
 
 
Figure 20. Search Page 
 
The user can then select any of the specific kinds of Pancreatitis that are displayed in the 
OMIM table, and then hit the button “show genetic information” in order to get detailed genetic 
information about this specific disease. The user can also click the button “select all” in order to 
select all of the specific kinds of Pancreatitis.  
In this use case, the user clicks the button “select all” and then clicks the button “show 
genetic information”. The system then gets the OMIM IDs and searches them into the ClinVar 
table in the central database in order to get all of the related genetic variations. The system also 
gets detailed genetic information for every genetic variation such as variant name, dbSNP ID, 
chromosome, clinical significance, reference allele, and alternative allele. Figure 21 shows the 
detailed genetic information related to Pancreatitis. The clinical significance types of the 
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identified SNPs include benign, likely benign, risk factor, uncertain significance, likely 
pathogenic, and pathogenic.  
 
 
Figure 21. Detailed Genetic Information Related to Pancreatitis 
 
In the “Analyze personal genetic variation data” page, the user can upload a VCF file and 
analyze it. In this use case, the user uploads a VCF file of 140 patients into the system. The 
system then processes the VCF file and identifies the SNP copies, reference, and alternative 
alleles for every patient. In the next step, the system executes the data analysis algorithms.  As 
shown in Figure 22, the user can also see the recently analyzed VCF files. 
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Figure 22. Analysis Page 
 
In the “Show group reports” page, the user can select the disease of interest from the 
dropdown list, and the name of the VCF file from the list of recently analyzed files, and then 
click the button “Show report” or “Show pharmacogenomic report”. The user needs to enter a 
key in order to be able to show these reports as shown in Figure 23. Figure 24 shows the final 
group report.  
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Figure 23. Show Group Report Page 
 
 
Figure 24. Group Report 
 
In the “Show individual report” page, the user can select the VCF file from the recently 
analyzed VCF files and enter the patient number. The user can then click the button “Show 
report” in order to view the final summary report as shown in Figure 25. 
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Figure 25. Show Individual Report Page 
 
In this use case, the user enters the patient number 122 and then clicks the button “Show 
report”. The generated report is shown in Figure 26. 
 
Figure 26. Final Report 
 
As shown in Figure 26, the final report provides information about the patient genetic 
variations related to the disease of interest and the corresponding pharmacogenomic information. 
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In this use case, patient 122 has one SNP related to Pancreatitis. Thus, the patient has a positive 
risk of Pancreatitis. Additionally, the final report provides links to the dbSNP and GenBank 
databases, and links to supporting papers about the SNP, the gene, and the corresponding 
pharmacogenomic information. Figure 27 shows the related dbSNP and GenBank records, which 
were obtained by clicking on the SNP ID (rs111033566) and the gene symbol (PRSS1) in the 
final report shown in Figure 27. 
 
Figure 27. Related dbSNP and GenBank Records 
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5.2.3 System performance 
The system was developed and tested using a Windows 7 machine with the following features: 
Intel core i7, CPU @ 2.20 GHz, and 8 GB RAM. MySQL community server version 5.1.73 was 
used to store different types of genomic data.  
Several factors affect the time required to analyze patients’ genetic variation data using 
our system, including the size of the VCF file, the number of patients in the VCF file, and the 
number of SNPs in the VCF file. We used our system to analyze three VCF files and we reported 
the time required to perform the analysis of every file. Table 10 provides the number of patients, 
number of SNPs, and the size of each file. Figure 28 shows the total analysis time for every VCF 
file.  




Patients No of SNPs 
Size 
(GB) 
File 1 140 552782 2.53 
File 2 3 1685578 2.24 










6.0  EVALUATION  
This chapter discusses the steps we have considered to evaluate the accuracy of the information 
and the analysis results provided by our system. 
6.1 ALGORITHMS EVALUATION  
Several steps were taken to evaluate the results of the extraction algorithms, which were used to 
extract the needed information from multiple data sources. The first step was to check the 
accuracy of the extracted data, which was done by performing SQL queries from the central 
database and comparing the results with the results from the existing databases such as dbSNP 
and ClinVar. The second step was to determine the integrity of the data in order to ensure that all 
genomic data stored in the database tables are consistent and meaningful. 
In order to evaluate the results of extracting the needed information from VCF files, we 
compared the output of our VCF information extraction algorithm with the output from the VCF-
Miner tool [221]. VCF-Miner is an existing tool for extracting genetic variation stored in the 
VCF file. We used our algorithm and the VCF-Miner to process and extract information from the 
same VCF file. We got the same number of genetic variations and the same number of samples 
for every variation. We also got the same detailed information about each variant such as 
chromosome, reference allele, alternative allele, and position in the chromosome. However, our 
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algorithm is able to extract the number of copies and the corresponding code of each variant in 
each patient. We need this specific information to be used in the data analysis algorithms in order 
to identify the patients with disease-associated genetic variations and pharmacogenomic 
associations. We customized the output of our algorithm to meet the format of the VCF-Miner 
output, so that we can easily compare the results. Figure 29 shows the output of our VCF 
information extraction algorithm and the output of VCF-Miner. 
 
Figure 29. VCF File Information Extraction 
In order to evaluate the data analysis algorithm that can identify patients’ genetic 
variations related to a disease of interest, our system was used to analyze multiple VCF files, 
such as VCF files for Pancreatitis, Cirrhosis, and Esophageal cancer. Each file contains genetic 
variations data from real patients who were diagnosed with one of the aforementioned diseases. 
Our system was able to screen these VCF files, analyze them correctly, and detect the patients 
who have genetic variations related to the disease of interest. 
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6.2 SYSTEM USABILITY STUDY 
6.2.1 Usability study methodology  
The purpose of this usability study was to evaluate the usability of the stand-alone system we 
have developed for managing and analyzing personal genomic data. The participating physicians 
were asked to use the system and fill out a questionnaire. The participating physicians were 
asked to do a few tasks, such as creating a user account, searching genetic variation information 
for a few diseases, viewing genomic analysis results, and viewing the final reports. The 
participating physicians were asked to fill out a paper-based questionnaire about the critical 
features of the system such as, security of the system, ease of use, and ease of accessing results. 
This paper-based questionnaire was distributed to the participating physicians before they 
perform the tasks on the system. The questionnaire has questions about specific tasks performed 
on the system.  This usability study was conducted in the participating physicians’ own offices or 
in the School of Health and Rehabilitation Sciences. (The usability study questionnaire is 
provided in Appendix B.) 
The study protocol was reviewed and approved by the University of Pittsburgh 
Institutional Review Board (IRB #: PRO15110267). The study was considered to be exempt 
because respondents were anonymous and there was no risk to participants. 
6.2.2 Usability study design 
The design of our usability study questionnaire was guided by the IBM post-study system 
usability questionnaire (PSSUQ) [222]. This PSSUQ aimed to address five system usability 
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characteristics: quick completion of work, ease of learning, high-quality documentation, 
functional adequacy, and rapid acquisition of usability experts [223].  
The usability study questionnaire is divided into five parts; four of them are related to 
four different tasks, and the last part includes post-task overall questions. The four tasks are as 
follows: 1) creating accounts in the system; 2) searching for diseases; 3) displaying the detailed 
genetic information related to the disease of interest; and 4) displaying the final genomic analysis 
report. The post-task overall questions assess physicians’ overall satisfaction with the system and 
the information provided by the system. 
6.2.3 Usability study results 
SPSS (Version 23) was used to analyze the result of the usability study questionnaire. All 
questionnaire results were tabulated and analyzed using descriptive statistics. 
6.2.3.1 Study population  
A total of six physicians from the University of Pittsburgh participated in this usability study. 
6.2.3.2 Task 1: Creating own account in the system 
All of the participating physicians reported that it is easy to create a username and password in 
the system (100%, n=6). Furthermore, all the participating physicians considered the system to 
be a secure system (100%, n=6).  
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6.2.3.3 Task 2: Searching for diseases 
All of the participating physicians reported that it is easy to search the genetic information 
related to a certain disease in the system (100%, n=6). Additionally, all of them reported that the 
search results are easy to read and understand (100%, n=6).  
6.2.3.4 Task 3: Displaying the detailed genetic information related to the given disease  
As shown in Figure 33, eighty four percent (84%, n=6) of the participating physicians reported 
that the system provides sufficient genetic information about the disease of interest. Additionally, 
all of them reported that this detailed genetic information is easy to read (100%, n=6). 
 
Figure 30. Genetic Information Provided in the System 
6.2.3.5 Task 4: Displaying the final genomic analysis report 
As shown in Figure 32, eighty four percent of the participating physicians reported that the report 
is well-formatted (84%, n=6). All of the participating physicians reported that the final genomic 
analysis report is easy to read and understand (100%, n=6). All of the participating physicians 
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reported that it is useful to include links to other important genomic databases such as dbSNP 
and GenBank (100%, n=6). 
 
Figure 31. The Final Report Format 
 
As shown in Figure 32, sixty seven percent (67%, n=6) of the participating physicians 
reported that the final report provides useful guidelines about each section in the report. One of 
the participating physicians suggested that the report can be improved by adding titles to each 
part of the report. Additionally, it is important to allow the user to hover over each part of the 
report in order to get a brief description. 
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Figure 32. Final Report Guidelines 
6.2.3.6 Post-task overall questions 
Overall, the participating physicians were satisfied with the system and the information provided 
by the system. Table 11 provides physicians’ responses to the post-tasks overall questions. 
Table 11. Post-tasks overall questions 
Question Yes No Number of Participants 
Percent 
Agreement 
Overall satisfaction with how 
easy is it to use the system.  6 0 6 100% 
It was simple to use the 
system. 6 0 6 100% 
I was able to complete the 
tasks quickly.  6 0 6 100% 
I felt comfortable using the 
system.  6 0 6 100% 
It was easy to learn to use the 
system.  6 0 6 100% 
It was easy to find the 
information I need.  6 0 6 100% 
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Table 11 (Continued) 
The information provided in 
the system is easy to 
understand.  
6 0 6 100% 
I liked using the interface of 
the system.  6 0 6 100% 
Overall, I am satisfied with 
using the system. 6 0 6 100% 
  
6.2.3.7 Recommendations 
Based on the information provided by the participating physicians in the usability study, we have 
considered certain changes in the system interface. Table 12 reviews the recommended changes 
and provides a brief justification of each change. 
Table 12. Recommended changes 
Change Justification  
Add titles for every part of the 
final report. 
These titles can increase the report’s usability 
by making it more scannable. 
Add tooltips (a message that 
appears when a cursor is 
positioned over a text) for every 
part of the final report. 
These tooltips can provide additional 
descriptions of the major parts of the report and 







7.0  DISCUSSION 
This chapter provides a discussion of the results and limitations of our survey study about 
physicians’ needs and expectations. The chapter also discusses the results of the system usability 
study and the limitations of the system. 
7.1 THE SURVEY OF PHYSICIANS’ NEEDS AND EXPECTATIONS 
Two alternative methods other than a survey could be used to collect qualitative data about the 
current status of using genomics in clinical practice and the expected features of a patient 
genomic information system. The first is an interview. In an interview, researchers can have a 
structured conversation with study subjects. Interviews can capture subjects’ points of view 
about a specific topic [224, 225] in depth. The second is a focus group. During a focus group 
study, a group of 6 to 12 [226] people are brought together by a researcher in a social space 
where the participants interact, discuss, and acquire knowledge about a specific topic [227, 228]. 
The researcher (also the moderator) can collect desired information by taking notes. 
Each method has its own advantages and disadvantages. Interviews provide an 
opportunity to explore topics in depth. The researcher (interviewer) can explain and clarify 
questions, which may increase the likelihood of receiving useful responses. The researcher can 
also ask further questions during an interview to gain more in-depth information. On the other 
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hand, the result of an interview is influenced by personalities, moods, and interpersonal 
dynamics between the interviewer and the interviewees. It can be difﬁcult to arrange a suitable 
place and time between researcher and interviewee, which usually results in a small number of 
people interviewed in a given period of time. 
A focus group generates quick and effective results. It is faster than an interview or 
survey [229]. It can produce high-quality data because the moderator can respond to questions 
and ask for clarification and more detailed responses [226]. On the other hand, focus group study 
has some disadvantages such as susceptibility to bias since the results can be affected by the 
researcher’s point of view [226]. Data from focus groups are difficult to analyze since the 
discussions should be audio-taped or videotaped in addition to the notes taken during the 
discussion. All these data should be transcribed verbatim. Although there are qualitative software 
programs such as NVivo that can review the transcribed reports and provide themes and 
graphics, the large volume of qualitative data may be difficult to analyze [230]. Furthermore, the 
results from focus groups are hard to be generalized to a larger population since they strongly 
depend on the participants’ selection and the small number of participants [230]. 
Given these disadvantages of interview and focus group methods, we decided to use the 
survey method to collect the information we need from physicians. Several reasons can justify 
our selection: 1) a survey can be administered remotely via the internet, which can reduce or 
prevent geographical dependence; 2) a survey can collect data from a large number of 
respondents; 3) numerous questions can be asked about a subject, which provides extensive 
flexibility in data analysis; and 4) some statistical techniques allow the researcher to analyze 
survey data and determine validity, and statistical significance. Surveys still have some 
disadvantages: respondents may not provide accurate answers and they may not feel comfortable 
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providing answers that present themselves in an unfavorable manner. Additionally, in the case of 
convenience sampling, the sample may not represent the population as a whole. Thus, the results 
of the survey can be biased.   
The survey study was a small exploratory study. However, analysis of the responses 
indicates that the majority of the participating physicians (73.33%) claimed to have sufficient 
knowledge in genomics (40% of them are quite familiar with genomics, 13.33% of them have 
extensive knowledge in genomics, and 20% of them are experts in the field). Additionally, the 
majority of them (86.67%) believed that genomics should be incorporated into the clinical 
practice, and they all agreed that genomics can improve clinical practice. Moreover, the majority 
of the participating physicians (92.85%) felt confident toward using genomics in personalized 
cancer treatment, and 64.29 percent of them indicated they are likely to order tests for a single-
gene-disorder. However, only 46.16 percent of them indicated they are likely to order tests for 
multiple-gene-disorder. 
At first glance, these numbers seem to be showing conflicting results: the majority of the 
physicians have sufficient knowledge in genomics and strong motivation to apply genomics into 
their clinical practice, on the other hand, close to half or more than half of them are unlikely to 
order tests for single- or multiple-gene-disorders. One reason that may justify this finding is that 
there are many conflicting research results reported in the current genetic and genomic research 
on diseases. Physicians need support from the research community to make selections on the 
most reliable research results. Before that support is available to some physicians, their best 
choice is probably not to order those genetic tests or genomic analyses [231].     
Based on the survey findings, we can find that physicians are willing and ready to 
incorporate genomics into their clinical practice. However, they need help or tools to do that. 
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One approach is to help them to make the appropriate selection on research results. Continued 
education is one of the strategies to enhance the physicians’ skill in selecting results from the 
latest genomics research. The other approach is to provide a patient genomic information system 
with their desired features: easy to use, secure, easy to access, and providing useful genetic 
information. 
A well-designed patient genomic information system for clinical purposes can help 
physicians to easily incorporate genomics into their clinical practice and to make their tasks more 
convenient. Our study identified physicians’ expectation about the features that motivate them to 
use a genomic information system. They should prove very helpful when people implement such 
systems in the future.  
This study has a number of limitations. First, the survey doesn’t assess all DOI domains 
that may affect the innovation diffusion such as personal factors or the environment in which the 
physician works. Second, our sample is a convenience sample of physicians at the University of 
Pittsburgh and the number of responders is small, which may narrow the confidence and 
generalizability of the findings. Third, the responses represent physicians’ self-reported data, 
which means that in some cases physicians might not provide accurate information.  
7.2 THE SYSTEM  
According to the current understanding between genetic variations and diseases, for most 
common diseases, the genetic variations identified in GWAS articles can increase the risk of 
developing the corresponding disease(s). However, patients who have some of those variations 
may not develop those diseases during their lifetime. In addition, these genetic variations may be 
 101 
helpful for diagnostic purposes, though they may not be very useful for the treatment of diseases 
if they do not have any pharmacogenomic consequences. After all, at this moment, technologies 
such as gene therapy are still not reliable. Therefore, physicians may not have a very strong 
motivation to use genomic information in their clinical practice [10]. The complexity of the 
genomic data and molecular biology databases also keeps physicians away from accessing 
genomic information. Our system is one step to help physicians utilize genomic information in 
their clinical practice. It also facilitates the translation of results from the study of human genetic 
variation into clinical practice, which is a desired goal of the current research and is likely to 
have the most immediate impact through pharmacogenomics studies [141] that aim to maximize 
the treatment benefit for the patient while minimizing the risk of adverse effects. As the 
understanding of genetic risk and its relationship to other risk factors becomes clearer, the 
opportunities for personalized medicine will increase. 
One limitation of our system is that it mainly uses the genetic variation results from the 
OMIM database and the GWAS method. Even though this approach can cover most available 
results in variation and disease association studies, it does miss results identified with other 
methods, which are not stored in the OMIM database.  
Another limitation of the system is that it does not take into account family relationships. 
It is actually quite common for multiple members of the same family to see the same doctor or 
go to the same hospital. Therefore, if their genomic information is available, it is likely to be 
stored in the same system. In this case, the system should be able to perform linkage analysis 
[139] and family-based analysis [232]. After all, genome sequences in family members are 
highly similar and the association between genetic variation and certain diseases can be more 
confidently determined than in a population samples with independent individuals.  
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The results of our system usability study indicate that physicians could easily find the 
patient information they need and the information can be directly applied in their clinical 
practice. Although the number of participating physicians in this usability study is small, it is 
clear that physicians are satisfied with the system and the information provided by the system. 
They appear to be willing to use the system in their clinical practices. Additionally, they are 
interested in seeing how the results from this system can change their diagnosis and treatment 
plans for their patients. One reason that may justify physicians’ satisfaction with our system is 
that the system was properly designed based on the desired features and suggestions obtained 
from the participating physicians in our survey study. These features help to motivate physicians 
to use a genomic information system in their clinical practice. 
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8.0  FUTURE WORK 
This research project provides a new resource to facilitate precision medicine, which is an 
emerging approach for disease treatment and prevention taking into account individual 
variability in genes, lifestyle, and environment of each person [12]. One future plan of this 
project is to integrate and connect the system with other systems, such as Electronic Health 
Records (EHRs). The information provided in our system can create great opportunities to 
influence clinical care. However, applications are limited by the current EHR designs.  
According to the Vanderbilt University Medical Center (VUMC), the design of a 
Pharmacogenomics-Enabled EHR should provide some basic functions [233] such as, providing 
timely access to clinically significant genetic variations; providing a preemptive identification of 
patients who are expected to benefit from the knowledge of genetic variation analysis in order to 
tailor future treatment options; facilitating genotyping of patients with immediate clinical needs; 
and rapidly distributing genetic analysis results to laboratory, patient portal, inpatient, and 
outpatient prescribing environments. 
The current EHR design requires significant modifications to incorporate genetic data in 
an actionable format [234, 235]. One limitation is the lack of structured data fields for storing the 
genetic test results in the EHR, which can be used for clinical decision support [236]. Even if 
these structured data fields are available, there is still uncertainty about how to report and 
integrate the genetic results with the existing clinical vocabulary.  
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Given the current limitations of EHR design, our system can act as an ancillary system 
for the EHR. This ancillary system has many advantages, such as reducing the storage 
requirements in the EHR since all of the patients’ genetic information will be stored in the 
ancillary system, and allowing for ongoing review and interpretation of the results as needed 
using algorithms that are not available in the EHR. 
The big data approach [237] can be used to integrate information from patients’ EHRs, 
mobile health apps, which can collect many types of patient information such as physical 
activities and diet, and the genomic information stored in this system.  Integrating all these types 
of data together can provide a comprehensive understanding about patients. This integration can 
lead to a significant improvement in the quality of health care.  
One future plan is to incorporate our system into a specific clinic such as a liver diseases 
clinic. In this case, the physician needs to identify the disease of interest and uploads a VCF file 
containing the genetic variations of his/her patients. The system will then analyze the VCF file, 
screen all of the genetic variations in this group of patients, and then identify the ones who have 
genetic variations associated with the disease of interest. Our plan is to follow the patients for a 
specific period of time, such as six months, and based on the analysis results provided by the 
system, we can determine how the system can affect the diagnosis and treatment options for 
patients. 
At this point, our system can handle and analyze uncompressed or compressed (*.gz) 
VCF files. Additional formats can be considered in the future. It is important to ensure that these 
VCF files are obtained from CLIA-certified laboratories, which comply with the federal Clinical 
Laboratory Improvements Amendments (CLIA) certification as administered by the Centers for 
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Medicare and Medicaid Services. CLIA creates quality standards to ensure the accuracy, 
reliability, and timeliness of patient test results [238].  
The pharmacogenomic information provided by our system is extracted from the 
PharmGKP database. Thus, the resulted pharmacogenomic associations are applied to the 
literature curated by PharmGKB. There may be more literature in the public domain to support 
or contradict the resulted associations. At this point, pharmacogenomic information provided by 









9.0  CONCLUSION  
Our survey study evaluated physicians’ status in using genomics in their clinical practice. Based 
on the survey findings, we realize that several factors affect the success in integrating genomics 
in clinical practices and the implementation of personalized medicine such as desired support or 
tools for physicians. Although physician’s knowledge in genomics has been enhanced in recent 
years, they still need support from the genomics community to make selections on the latest 
research results. The desired genomic information management system should have the ability to 
make all physician-desired data readily accessible to physicians in a convenient manner. 
In this research project, we have developed a system to manage and analyze large 
amounts of genomic data and to enable convenient extraction of genetic information for 
physicians. Our system provides one encapsulated and presentable place for various types of 
genomic information needed by physicians, so that they can conveniently access the desired 
patient’s genetic information and current research results at a single place. The system is able to 
screen and analyze all of the genetic variations in the patient and then identify the genetic 
variations that are associated with the disease of interest. The system identifies the clinical 
significance of every single genetic variation in the patient. It also provides the corresponding 
pharmacogenomic information for every patient. One important advantage of the system is that it 
allows physicians to get their desired results without extensive training in genomics. The results 
of our system usability study indicate that physicians are satisfied with the system and the 
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information provided by the system. They appear to be willing to use the system in their clinical 
practices. Additionally, they are interested in seeing how the results from this system can change 





1) Please indicate your gender:  
A: M.  
B: F.  
2) Which age range are you in?  
A: <= 30.  
B: 31-35.  
C: 36-40.  
D: 41-45.  
E: 46-50.  
F: 51-55.  
G: 56-60.  
H: >60.  
3) Please indicate your field of practice (listed alphabetically):  
A: Cardiology.  
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B: Dentistry.  
C: Dermatology.  
D: Endocrinology.  
E: Family.  
F: Gastroenterology.  
G: General.  
H: Hepatology.  
I: Nephrology.  
J: Neurology.  
K: OB/GYN  
L: Oncology.  
M. Ophthalmology.  
N: Otolaryngology.  
O: Pediatrics.  
P: Pulmonology.  
Q: Rehabilitation.  
R: Rheumatology.  
S: Other (please specify):-------------------------------------------------  
4) How many years of experience in medical practice do you have?  
A: 1-5.  
B: 6-10.  
C: 11-15.  
D: 16-20.  
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E: 21-25.  
F: 26-30.  
C: More than 30 years.  
Knowledge 
5) How would you rate your overall knowledge in genetics?  
A: I know nothing about genetics or genetic tests.  
B: I have some basic understanding about the principles of genetics.  
C: I am quite familiar with genetics terms and tests.  
D: I have extensive knowledge.  
E: I am an expert in the field, and highly confident in dealing with genetic information.  
6) Do you agree that enhancing your knowledge in genetics may be beneficial to your patients?  
A: Strongly disagree.  
B: Disagree.  
C: Neutral.  
D: Agree.  
E: Strongly agree.  
General Opinions 
7) Do you believe that genetic testing should be incorporated into clinical practice?  
A: Strongly disagree.  
B: Disagree.  
C: Neutral.  
D: Agree.  
E: Strongly agree.  
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8) Which of the following reasons would motivate you to seek genetic information for patient 
care? 
A: Single-gene disorders.  
B: Newborn screening.  
C: Cancer.  
D: Multi-gene disorders.  
E: Pharmacogenomic breakthrough.  
F: Other (please specify):-------------------------------------------------  
9) Do you believe that new findings in genetics can change clinical practice, even though it may 
or may not be true in your particular field?  
A: Strongly disagree.  
B: Disagree.  
C: Neutral.  
D: Agree.  
E: Strongly agree. 
Specific Tests 
10) How likely are you to order tests for common single-gene disorders?  
(For example, the BRCA1 or BRCA2 mutations linked to hereditary breast cancers. Many cases 
of cystic fibrosis can be traced back to a mutation in the CFTR gene.) 
A: Very unlikely.  
B: Somewhat unlikely.  
C: Neutral.  
D: Somewhat likely.  
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E: Very likely. 
F. Not Applicable 
11) How likely are you to order sophisticated genetic tests for complex multiple-gene disorders?  
(For example, asthma, Alzheimer's, cancer, cardiovascular disease, obesity, and restless leg 
syndrome (RLS).)  
A: Very unlikely.  
B: Somewhat unlikely.  
C: Neutral.  
D: Somewhat likely.  
E: Very likely. 
F. Not Applicable 
12) Do you agree that patients’ genetic information should be used to guide decisions about 
medication utilization or dosage? 
A: Strongly disagree.  
B: Disagree.  
C: Neutral.  
D: Agree.  
E: Strongly agree. 
F. Not Applicable 
13) Do you believe that genetics can be used to predict adverse drug reactions for some patients? 
A: Strongly disagree.  
B: Disagree.  
C: Neutral.  
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D: Agree.  
E: Strongly agree. 
F. Not Applicable 
14) How confident are you that genetics will be used as a method for personalized cancer 
treatment for patients in the next 10 years?  
A: Very unconfident.  
B: Somewhat unconfident.  
C: Neutral.  
D: Somewhat confident.  
E: Very confident. 
F. Not Applicable 
15) Please indicate your level of confidence in your ability to make medical recommendations 
based on genetic data obtained from genetic testing:  
A: Very unconfident.  
B: Somewhat unconfident.  
C: Neutral.  
D: Somewhat confident.  
E: Very confident. 
16) How likely are you to need to consult with genetic counselors or specialists to interpret the 
result of a genetic test?  
A: Very unlikely.  
B: Somewhat unlikely.  
C: Neutral.  
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D: Somewhat likely. 
E. Very likely. 
F. Not Applicable 
17) What is the lowest level of accuracy that you would accept from genetic testing reports? 
A: Completely wrong.  
B: A number of errors in the report.  
C: Normal range of error rates in a medical report.  
D: A small number of errors or uncertainty in the report.  
E: Completely correct (no errors at all). 
F. Not Applicable 
18) How often do you believe that genetic testing reports need to be updated? 
A: Every week.  
B: Every month.  
C: Every 6 months.  
D: Once a year.  
E: Every two years.  
G: Every ten years.  
H: No need to make update on the report. 
19) How likely would you be to use a patient’s family history to support clinical decisions? 
A. Very unlikely 
B: Somewhat unlikely.  
C: Neutral.  
D: Somewhat likely.  
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E: Very likely. 
Expected Features from a Patient Genome Information Management System 
(A patient genomic information system aims to integrate genetic information from multiple 
sources, integrate them, and organize them into standard format.) 
20) Do you agree that genetic information management systems should be easy to search based 
on keywords such as disease name? 
A: Strongly disagree.  
B: Disagree.  
C: Neutral.  
D: Agree.  
E: Strongly agree. 
21) Do you agree that the information used for interpretation in a genetic information 
management system should be updated periodically (for example, every month, twice a year, or 
once a year) to keep pace with new clinical observations and validated research findings?  
A: Strongly disagree.  
B: Disagree.  
C: Neutral.  
D: Agree.  
E: Strongly agree. 
22) Do you agree that genetic information management systems should be comprehensive 
(including complete information about diseases, related genetic variations and genes, and 
pharmacogenomic information)?  
A: Strongly disagree.  
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B: Disagree.  
C: Neutral.  
D: Agree.  
E: Strongly agree. 
23) Do you agree that genetic information management systems should be easy to use and 
provide information/recommendations in an easy to interpret format?  
A: Strongly disagree.  
B: Disagree.  
C: Neutral.  
D: Agree.  
E: Strongly agree. 
24) Do you agree that genetic information management systems should provide some 
explanation for genomic test result interpretations?  
A: Strongly disagree.  
B: Disagree.  
C: Neutral.  
D: Agree.  
E: Strongly agree. 
25) Do you agree that genetic information management systems should be easily accessible 
(available anytime and anywhere, i.e, through an online portal)?  
A: Strongly disagree.  
B: Disagree.  
C: Neutral.  
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D: Agree.  
E: Strongly agree. 
26) If you were to get a genetic testing report for your patient from a personal genome 
information management system, where would you prefer to store it?  
A: In the EHR system I use to store all other patient information.  
B: In a separate database.  
C: On my local hard drive or an external hard disk.  
D: On a CD/DVD.  
E: On a flash drive.  
F: Other:------------------------------------- 
27) How long do you believe genetic test reports should be stored?  
A: 1 - 3 months.  
B: 4 - 6 months.  
C: 7 months- 1 year.  
D: 1 year- 3 years.  
E: More than 3 years. 
F. Whatever hospital administrators decide is an acceptable length of time. 
28) What is the biggest hindrance to using genetic information in your clinical practice?  
A: How to order the genomic tests.  
B: Which test to choose.  
C: Whether or not I can understand the report.  
D: Security and privacy of patient’s genetic information.  
E: Insurance.  
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F: The accuracy of the report  
G: The usefulness of the result to my treatment plan  
H: Other:--------------------------------------- 
29) Do you believe genetic information should be encrypted?  
(Encryption/Decryption slows down the performance of a genetic information management 
system, but encrypted information is secure as long as the encryption key is protected properly.)  
A: Yes.  
B: No. 
30) Please indicate whether you have ordered any genetic tests before you completed this survey  
A: Yes.  
B: No. 
31) If your answer in question 30 is yes, please list the tests that you most frequently ordered. 
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Appendix B 
USABILITY STUDY QUESTIONNAIRE 
Guideline: This questionnaire is divided into five parts, which are corresponding to the four 
tasks you will perform in this study. You will be asked to perform each task and then answer the 
questions related to that task. The last part is for overall questions about the system. 
Task 1: Create your own username and password in the system 
Q1) Is it easy to set up an account in this system?  
A. Yes. 
B. No 




Q3) Do you consider the system secure? 
A. Yes. 
B. No 




Task 2: In the “Search” page, type “Pancreatitis” in the search area and then click on the 
search button. 








Q7) Is the information provided in the system accurate?  
A. Yes 
B. No. 




Q9) Do you believe the search results provided in the system are easy to read and understand? 
A. Yes 
B. No. 




Task 3: Click on the first record in the search result table in order to access a complete set 
of detailed genetic information related to the disease.  
Q11) Do you believe the system provides sufficient genetic information about the disease for 
physicians to order genetic tests and to understand the genetic foundation of the disease? 
A. Yes 
B. No. 
Q12) If your answer is No, please suggest another type of genetic information that needs to be 












Task 4: In the “Show Report” page. Select the disease “Pancreatitis” from the drop down 
list, and type 122 in the patient ID textbox, and then click on the “Show report” button. 
Q15) Is the final genomic analysis report easy to read? 
A. Yes. 
B. No. 




Q17) Do you believe the report is well-formatted? 
A. Yes.  
B. No. 





Q19) Do you believe the report provided in the system is easy to understand? 
A. Yes. 
B. No. 













Q23) Do you believe it is useful to include links to other important genomic databases such as 
dbSNP and GenBank in the report? 
A. Yes. 
B. No. 
Q24) If your answer is No, please suggest the resources you want in the report, or indicate that 
you do not need or use any of these links.  
Overall Questions 
Q25) Overall, I am satisfied with how easy it is to use this system 
A. Yes. 
B. No. 
Q26) It was simple to use this system. 
A. Yes. 
B. No. 
Q27) I was able to complete the tasks and scenarios quickly using this system. 
A. Yes. 
B. No. 




Q29) It was easy to learn to use this system. 
A. Yes. 
B. No. 
Q30) It was easy to find the information I needed. 
A. Yes. 
B. No. 




Q32) I liked using the interface of this system. 
A. Yes. 
B. No. 
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